¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/19 ¤W¤È 10:04:53
²Ä 3983 ½g¦^À³
|
2022¦~©³¡A¦ôp ¤w¦A¦¸¼W资¦ô20%+(14.000¤dªÑx20¬ü¤¸/ADR¡A2.8»õ¬ü¤¸¡AªÑ¥»¼W¥[¦Ü84,000¤dªÑADR «D¬ü区ASlAN004¡A ¾P°âÅv±ÂÅv§¹¦¨¡A¶Ò±o²{ª÷约3»õ¬ü¤¸
42+2.8=44.8»õ¬ü¤¸§é现È
44.8»õ¬ü¤a/84,000¤dªÑADR=53¬ü¤¸¡C
¨CªÑ³Q¨ÖÁÊ谮¦b²{È53¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/19 ¤W¤È 09:56:42
²Ä 3982 ½g¦^À³
|
42»õ¬ü¤¸§é²{¼çÈ
§ë³ø²v¼ç¤O¶W¹L13¿/(2¦~¤º) ªº¥Í§Þ¶Â°¨¡X¡X
¨È·à /ASLAN004 , ¼ç¦b³Q¨ÖÁʲ{È42»õ¬ü¤¸ VS. 2.7»õ¥«È
REGEN /Dupilumab CEO«Å¥¬ ¥¼¨Ó¦~¾P°â°ªÂI¦ô120»õ¬ü¤¸(AD/ý³Ý/COPD)¡A«Å¥¬«á6Ó¤ëªÑ»ù¥«³õµ¹¤©300»õ¬ü¤¸ªº¦^³ø
¥Ø«e¨È·à±d¤½¥qªº³Q¨ÖÁÊ»ùȦôp:
©ú¦~©³°µ§¹(2022¦~©³) ASLAN004 AD 2b Á{§É¡Ï ý³Ý 1b Á{§É ¡Ï ASLAN003 MS 2a Á{§É
¼ç¦b³Q¨ÖÁʲ{ª÷¥«È¦ô: 30e¬ü¤¸¡]¥Ø«eAslan004 §é²{È)¡Ï3e¬ü¤¸§é²{¼WÈ¡Ï4e¬ü¤¸2b°µ§¹¼WÈ ¡Ï5e¬ü¤¸/aslan003=42»õ¬ü¤¸¡X-
ASLAN004 ³Ì°ª¾P°â 60»õ¬ü¤¸ ASLAN003 ³Ì°ª¾P°â10»õ¬ü¤¸ ¡X¡X¡X- 42»õ¬ü¤¸/70,000¤dªÑADR(¥Ø«eªÑ¥»70,000¤dªÑ-- ¥¼§t4,000¤dªÑADR, ¥¼¨Ó0¦~¥¼©w»ùªº»{ÁÊÅv)
= 50¬ü¤¸-ADR
¨CªÑADR ¼ç¦b³Q¨ÖÁÊ»ùÈ 50¬ü¤¸( 2022¦~©³)
¡X¡X¡X¡X¡X¡X
¥t¨ÖÁʪ̶·¤ä¥I ¤W´åCSL/Aslan004¤Î Almirall/Aslan003ªº¶RÂ_ ¦X¬ù ±ø¥óªºª÷ÃB¡C CSL ¦ô17»õ¬ü¤¸ªº²{È(2022¦~©³) Almirall ¦ô 2.5»õ¬ü¤¸ªº²{È¡]2022¦~©³)
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥«³õÄvª§ ¤@¡AÀø®Ä: 1.ASLAN004 1b Àu¶Õ ADÁ{§É¼Æ¾Ú VS Dupilumab 3 ´Á AD ,
1.1 ASLAN004 1b´Á¤¤¸Ñª¼³ø§i 400mg /600mg EASI-75 (¤T´Á¥Dn«ü¼Ð¤§¤@)¹F67% ¹ï·Ó²Õ¬°0%, Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g EASI-75 =50% , ¹ï·Ó²Õ¬°13.5%
Aslan004 1b /Dupilumab p3/QW=67%/50%=134%. (°ò½u¼ÆȬ۪ñ)
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
1.2 ASLAN004 1b´Á¤¤¸Ñª¼³ø§i 400mg /600mg EASI-50(ªvÀø16¶g«á¥¼¹FEASI-50ªÌ,«OÀI¤½¥q¤£¦A¤ä¥I) ¹F89% ,¹ï·Ó²Õ¬°40%, Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g EASI-50 =61% , ¹ï·Ó²Õ¬°23.5% Aslan004 1b /Dupilumab p3/QW=89%/61%=146%. (°ò½u¼ÆȬ۪ñ)
1.3 ¸gÀٮįq®t²§ EASI-75= +34% + EASI-50=+46%/2= 23% =57% Aslan004 1b ¸gÀٮįq Àu©ó Dupilumab 57% ªº¼ç¤O(°²³]¥¼¨ÓÀøµ{¶O¬Û¦P)
1.4 Dupilumab ¥DnÀø®Ä«ü¼ÐIGA 0/1 °ª1.33~2¿ ©ó¨ä¥L ¥u¯à§í¨îIL-13¡Ï³¡¤ÀIL-4/ ³æ§í¨îIL-13 ªº Lebrikiumab 75% of dupilumab /Tarlokinumab 50% of dupilumab
2.¦w¥þ©Ê/°Æ§@¥Î :ASLAN004 µL Dupilumab ªº°ª¤ñ²vµ²½¤ª¢.
3.¥´°wÀW²v ASLAN004 ¥|¶g¤@°w 600mg*4=2400mg ¹w´Á VS. Dupilumab*¤G¶g¤@°w/ 300mg*9=2700mg
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¡X¡X¡XÁo©ú¸êª÷¡A¦Û·|§ä¥X¸ô¡I¡X¡X¡X
¸ê°T¤£¹ïºÙ»ùÈ
¬ü¡B¥xªÑ¥«©|¥¼¤ÏÀ³ 1.¨È狮»PCSL¦@¦P¶}µoASLAN004¨ì1aÁ{§É§¹¦¨ªº§Q¯q¡C 2019/05/31¤w¸g°ê»Ú±ÂÅv¡A¨È·à©Ò±o§Q¯q¦ô§é现È10»õ¬ü¤¸¡C¥tCSL¥ç±o10»õ¬ü¤¸ªº¼ç¦b§Q¯q¡A¦@20»õ¬ü¤¸¡C ñ约°ò¦¡A°Ñ¦Ò°ê»Ú¦P级¦X¬ù¡A¦ô³Ì°ª销°â30»õ¬ü¤¸¡C (·í®ÉDupilumab ¥«³õ»{¦P¥¼¨Ó³Ì°ª¥i销60»õ¬ü¤¸)
2.2020¦~¤¸¤ë Dermira/Lebrikizumab AD ªº¨ÖÁʧé²{»ùÈ 29»õ¬ü¤¸. 2020/01 §¨Ó¨ÖÁÊDermira ¤½¥q
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 11»õ¬ü¤¸+18»õ¬ü¤¸=29»õ¬ü¤¸,
3.2020/7/13
a.¦]Dupilumab ¥«³õ»{¦P°ª¾P°âÃB´£¤É¨ì120»õ¬ü¤¸¡C ASLAN004ÀH¥«³õÂX¤j¡A¥¼¨Ó·s°ê»Ú±ÂÅvÈ¨Ì¾Ú ³Ì°ª¾P°â¦ô¥i¹F60»õ¬ü¤¸
b¡D2020¦~¤¸¤ë§¨Ó¨ÖDermiraªº§é现»ù¡A¤w¹F29»õ¬ü¤¸¡C LebriKiulmabªº¤T´Áý³Ý¡A2017¦~¸Ñª¼¥¢±Ñ¡CªÍ³¡C0PD¥ç¥¢±Ñ¡C
Dermiraªº§é现»ùLebriKiulmab¥u¦³ AD ¾AÀ³¯g¡A¤w¹F29»õ¬ü¤¸ ASLAN004 ¦P Dupilumab Àø®Ä¥i¬° LebriKiulmab 1/0.75=1.33¿
29*1.33=38.7 »õ¬ü¤¸
C¡D¨È·à ý³Ý/ªÍ³¡COPD¨â¤j¾AÀ³¯g¦¨¥\¦Pdupilumab¾÷·|¡C ¦ôp ¾P°â°ªÂI¦³10»õ~15»õ¬ü¤¸ªº¾P°â»ùÈ.
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X 4. 4.1¥¼¨ÓªºASLAN004 ±ÂÅv¦X约±ø¥ó: ¦ôp ±ÂÅvª÷30»õ¬ü¤¸+销°â¤À¼í¡]隠§t60»õ¬ü¤¸³Ì°ª¾P°â¡^ §é²{È45»õ¬ü¤¸¡C
¨È狮¥i¤À30»õ¬ü¤¸+2bÁ{§É»ùÈ4»õ¬ü¤¸+§é²{¼WÈ3»õ¬ü¤¸=37e¬ü¤¸¡C(2022¦~©³)
4.2¥¼¨ÓªºASLAN003 ±ÂÅv¦X约±ø¥ó: ¦ôp ±ÂÅvª÷5»õ¬ü¤¸+销°â¤À¼í¡]隠§t10»õ¬ü¤¸³Ì°ª¾P°â¡^ §é²{È7.5»õ¬ü¤¸¡C
¥tASLAN003 ¦ô²{ª÷»ùÈ=5»õ¬ü¤¸---¨È·à±d¤½¥q¿W±o
¦Xp 42»õ¬ü¤¸ §é²{È-----¨È·à±d¤½¥q¿W±o
***¥t¥~ CSL¥i±o17»õ¬ü¤¸ §é²{È Almirall ¥i±o2.5»õ¬ü¤¸ §é²{È |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/19 ¤W¤È 09:48:17
²Ä 3981 ½g¦^À³
|
seekingalpha.com/article/4414673-aslan-next-generation-dupixent-potential-5x-return?utm_source=stck.pro&utm_medium=referral
ASLAN Pharmaceuticals: A Next-Generation Dupixent And Potential 5x Return In A Year
ASLAN药业¡C·s¤@¥N§ù¤ñ´ËDupixent©Mýͦbªº5¿¦^报²v¦b¤@¦~内实现¤F
¦¹½g³ø§i¡A¦³¤U¦C¤£¨¬¤§³B 1.Àø®Än¤ñ¸û¡A¥²¶·¦b¨âÁ{§Éªº±wªÌ¦b°ò½u(Á{§É«eªºÀËÅç)¡A¦³±µªñªº¯f¯g¡A¦pEASI¡BIGA=4.....¡A¥¼¥æ¥N 2.°ê»ÚLebrikizumabAD±ÂÅv¨ÖÁʦ污,¥æ¥N¤£§¹¥þ¡A¥¼ºâ¾ãÅé±ÂÅv»ùÈ(29»õ¬ü¤¸ªº¨ÖÁʦ¨¥»)¡A谮¦b¾P°ªÂI¥¼¦ô¡C 3.¹ïCSL©M¨È狮±dªº2014¦~¶}©l¡A¦@¦P¶}µo§Q¯q¥¼¦ôp¡C 4.¥u¥DÆ[¥æ¥N¥¼¨Ó¤@¦~¦³5¿ªº§ë³ø¹S¡A¥¼¸Ô²Ó¤º®e»¡©ú¡C
5.Á{§É¼Æ¾Ú¥¼¥I»P»ùÈ®t²§µû»ù
6.¥¼¦ô¡AASLAN004¾P°â°ªÂI¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/19 ¤W¤È 08:25:15
²Ä 3980 ½g¦^À³
|
¥H¤U¤£¬O¹Ú¡A¦ý³Ì¦n¥Ñ«e¤¤jÃļt¨Ó°õ¦æ¡A¤è¯à¥i¾AÀ³¯g§Ö³t¤W¥«¡C nªáªºÁ{§É费¡A¯uªº¤£§C¡C
Dupilumab ¤wªá¶W¹L50»õ¬ü¤¸ªº¬ãµo费¡C
ASLAN004 AD¤Îý³Ý³Ì¨ÎÀøªk¼ç¤O ---ASLAN004 1b ´Á¤¤ AD ¸gÀٮįq57% Àu©óDupilumab 3´Á
¨Ì¾ÚEylea vs Lucentis ,
-----Eylea¸gÀٮįq35% Àu©ó Lucentis
¾P°â¥«³õÂX¥R¼Ò¦¡ ¡A
ASLAN004 ¥¼¨Ó¤W¥««e¥|¦~ ¾P°â¦ôp¦p¤U
ASLAN004 ¾P°â¦ôdupilumab(2026-2029)
¦ôp2026¦~¤W¥«²Ä¤@¦~¾P°â 36»õ¬ü¤¸¬°dupilumab 30%(120*30%=36) ²Ä¤G¦~¾P°â 60»õ¬ü¤¸¬°dupilumab 50%(120*50%=60) ²Ä¤T¦~¾P°â 78»õ¬ü¤¸¬°dupilumab 65%(120*65%=78) ²Ä¥|¦~¾P°â115»õ¬ü¤¸¬°dupilumab 120%(96*120%=115),
-------- Dupilumab ¹w¦ô120»õ¬üª÷³Ì°ª¦~¾P°â(¬ü°êªÑ¥«¥«³õ»{µý),2020¾P40»õ¬ü¤¸, 2021¦ô¾P57»õ¬ü¤¸. --------
¥«³õÄvª§ ¤@¡AÀø®Ä: 1.ASLAN004 1b ´Á¤¤ADÁ{§É/QW*8¶g Àu¶Õ¼Æ¾Ú VS Dupilumab 3 ´Á AD /QW*16¶g ,
1.1 ASLAN004 1b´Á¤¤¸Ñª¼³ø§i 400mg /600mg EASI-75 (¤T´Á¥Dn«ü¼Ð¤§¤@)¹F67% ¹ï·Ó²Õ¬°0%, Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g EASI-75 =50% , ¹ï·Ó²Õ¬°13.5%
Aslan004 1b /Dupilumab p3/QW=67%/50%=134%. (°ò½u¼ÆȬ۪ñ)
¥DnÀø®Ä«ü¼Ð Aslan004 1b Àu34% ©ó Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g
1.2 ASLAN004 1b´Á¤¤¸Ñª¼³ø§i 400mg /600mg EASI-50(ªvÀø16¶g«á¥¼¹FEASI-50ªÌ,«OÀI¤½¥q¤£¦A¤ä¥I) ¹F89% ,¹ï·Ó²Õ¬°40%, Dupilumab 3 ´Á,¨C¶g¤@°w*16¶g EASI-50 =61% , ¹ï·Ó²Õ¬°23.5%
Aslan004 1b /Dupilumab p3/QW=89%/61%=146%. (°ò½u¼ÆȬ۪ñ) ¦¸nÀø®Ä«ü¼ÐEASI-50 ,
Aslan004 1b Àu46% ©ó Dupilumab 3 ´Á
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
1.3 ¸gÀٮįq®t²§ EASI-75 34% + EASI-50, +46%/2= 23% =57%
Aslan004 1b ¸gÀٮįq Àu©ó Dupilumab 3 ´Á 57% ªº¼ç¤O(°²³]¥¼¨ÓÀøµ{¶O¬Û¦P)
( Dupilumab ¥DnÀø®Ä«ü¼ÐIGA 0/1 °ª1.33~2¿ ©ó¨ä¥L ¥u¯à§í¨îIL-13¡Ï³¡¤ÀIL-4/ ³æ§í¨îIL-13 ªº Lebrikiumab 75% of dupilumab /Tarlokinumab 50% of dupilumab)
2.¦w¥þ©Ê/°Æ§@¥Î :ASLAN004 µL Dupilumab ªº°ª¤ñ²vµ²½¤ª¢.(38%%¦³µ²¼Òª¢, ¹ê»Ú¨Ï¥Î241¤H¬ã¨s®×)
3.¥´°wÀW²v ASLAN004 ¥|¶g¤@°w 600mg*4=2400mg ¹w´Á VS. Dupilumab*¤G¶g¤@°w/ 300mg*9=2700mg
----------------------------------- Eylea ¥«³õ°»ù66.6%,¥«³õ¾P°âÂX¥R76»õ¬ü¤¸¡AÂX¥R²v176%. ¥«Ô·º¯³z²v(¤H¼Æ)ÂX¥R265%,(176%/66.6%=265%)
2015 Lucentis ³Ì°ª¾P°â43»õ¬ü¤¸ 2019¦~ ¨âÃľP°â¦Xp119»õ¬ü¤¸
¨ì2019¦~¥«³õ¼W¥[119-43=76»õ¬ü¤¸
76/43=176% ¼W¥[²v.-----(¥¼º¡¨¬¥«³õ,°»ù¬O¦³¥Îªº)
2012: Eylea ¤W¥«²Ä¤@¦~¾P°â¬°Lucentis¤w¤W¥«6¦~ 36%. 2013: Eylea ¤W¥«²Ä¤G¦~¾P°â¬°Lucentis¤w¤W¥«7¦~ 51%. 2014: Eylea ¤W¥«²Ä¤T¦~¾P°â¬°Lucentis¤w¤W¥«8¦~ 65%. 2015: Eylea ¤W¥«²Ä¥|¦~¾P°â¬°Lucentis¤w¤W¥«9¦~ 120%.
2012 ¨âÃľP°â¦Xp32.7»õ¬ü¤¸ 2013 ¨âÃľP°â¦Xp50.96»õ¬ü¤¸ 2015 ¨âÃľP°â¦Xp74.8»õ¬ü¤¸ 2016 ¨âÃľP°â¦Xp88.38»õ¬ü¤¸ 2019 ¨âÃľP°â¦Xp119»õ¬ü¤¸
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70**B/A=36%**32.7 --------(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43**B/A=51%**50.96 ¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38**B/A=161%**88.38 2017¡V33.00//62.82**B/A=190%**95.82 2018¡V37.00//67.00**B/A=181%**104 2019¡V41(¦ô)//78.52**B/A=191%**119
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AMD¡X¡X°w¾¯ Ävª§¥v¡]ªvÀø¡X²´·ú¶À¯Z³¡¯fÅÜ¡^ ¤@¡BLucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ¡A¨C¤ë¤@°w¡A¨C¦~24,000¬ü¤¸Àøµ{¶O¥Î
¤G¡BEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A¨C2¤ë¤@°w¡A¨C¦~16,000¬ü¤¸Àøµ{¶O¥Î¡C
Lucentis¡]Ranibizumab¡^ ©MEylea¡]aflibercept¡^ ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C
¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/18 ¤U¤È 10:37:42
²Ä 3979 ½g¦^À³
|
§Úı±o·à¤l¦A¨Ó«ÜÃø§C©ó4¤¸¥H¤U¤F ·Q½æªº³£½æ±o®t¤£¦h «á¶Õ¬Ý¦n |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/18 ¤U¤È 10:34:27
²Ä 3978 ½g¦^À³
|
seekingalpha.com/article/4414673-aslan-next-generation-dupixent-potential-5x-return?utm_source=stck.pro&utm_medium=referral
ASLAN Pharmaceuticals: A Next-Generation Dupixent And Potential 5x Return In A Year ASLAN药业¡C·s¤@¥N§ù¤ñ´ËDupixent©M潜¦bªº5¿¦^报²v¦b¤@¦~内实现¤F
Mar. 18, 2021 9:00 AM ETASLAN Pharmaceuticals Limited (ASLN)
·§n Aslan Pharma¥¿¦b开发ASLN004¡A这¬O¤@个潜¦bªº数¤Q亿¬ü¤¸ªº药ª«¡A¥Î¤_¥þ²y¥«场ªº¯S应©Ê¥Öª¢©Mý³Ý¡C
该药ªº§@¥ÎÉó¨îÉO赛诺µá©MRegeneronªºDupixent°ª«×¬Û¦ü¡A¦ZªÌ¦b2021¦~¥þ²y销¶q¶W过40»õ¬ü¤¸¡C
³Ìªñ¡AAslan¦b¤@个¤p队¦Cªº¯S应©Ê¥Öª¢±wªÌ¤¤报§i¤F¤Þ¤Hª`¥ØªºASLN004数Õu¡C
Aslanªº¥ø业ɲȤ£¨ì200MM¡F¥¦ªºÉ²È¦ü¥G³Q°ª«×§C¦ô¡C
Summary Aslan Pharma is developing ASLN004, a potential billion-dollar drug for the global markets of atopic dermatitis and asthma. The drug¡¦s mechanism of action is highly similar to Sanofi and Regeneron¡¦s Dupixent which sold over $4BB worldwide in 2021. Aslan recently reported striking ASLN004 data in a small cohort of atopic dermatitis patients. Aslan has an enterprise value of under $200 MM; it appears highly undervalued.
¬Û¹ï±M·~ªº¤ÀªR
¹q³X¹L¤G¦¸ ¨È·àCEO ³Å«i ------------------ 3¤ë1¤é¦¬¥«¦Z¡AAslan«Å¥¬发¦æ60MM¡AªÑɲ¤j¶^¡C该¤½¥q显µM»Ýn资ª÷来资§U¨ä2b´Á¬ã¨s¡A计¦E¤_2021¦~¤U¥b¦~开©l¡A¦]¦¹¦b积Ì媺数Õu¤§¦Z¡A发¦æ¤£应该¬O¤@个¥¨¤jªºÕa³ß¡CµM¦Ó¡AÉO³Ìªñ许¦h¥Íª«§Þ术¥æ©ö¤£¦Pªº¬O¡AªÑ²¼经±`¦b¥æ©ö¤¤¤Ï弹¡A¦ý这Ïú±¡况¦}没¦³发¥Í¡C
抛°â¥i¯à¬O¥ÑEvaluate Vantageªº¤@½g题为¡G¦´Á数Õu´£®¶Aslan¡A¦ý¤£n©¿视¦M险«H号 ªº¤å³¹¤Þ°_ªº¡C§@ªÌAmy Brown写¹D¡A¦³2个问题应该¤Þ°_Aslan§ë资ªÌªº关ª`¡Ga)ASLN¡¦004ªºª«质ÌÛ¦¨将¤_2027¦~¨ì´Á¡Fb)Aslan将¥H¨½µ{¸O©Mª©税ªº§Î¦¡¤í许¥i¤èCSL¬Û当¤jªº¤@笔钱¡C
这两点³£«Ü¤½¥¡A¦ý§Ú·Q¦^应¦p¤U¡G
a)过¥h两©P§ÚÉOAslan CEO Carl Firth谈过两¦¸¡A
¥L认为¡A随着¥Íª«¨î«~©M¨ä¥L©µ´Á¡B¤w经¥Ó请¦}¤½¥¬ªº剂¶q专§Q¥H¤Î证©ú¥Íª«¬Û¦ü©Ê©Ò»Ýªº时间¡A¤½¥q¦b2040¦~¤§«e¥i¯à³£没¦³问题¡C
b)±µ¤U来¡A虽µM¤ä¥I给CSLªº´Ú项«Ü¦³·N义¡A¦ý¡¦004¦bAD¡Bý³Ý¡A©Î许还¦³¨ä¥LÓì应¯gªºÉó会¨¬够¤j¡A§Y¨Ï¡¦004¦b°ª®p´Á¥u实现1 BBªº销°â额¡A¤£¨ì§ù¤ñ´Ë¯S预´Á°ª®p´Á销°â额ªº10%¡A这¨Ç¦¬¤J¤]会给¤½¥q带来«Ü¤jªº¤W¤ÉªÅ间¡C
§Ú认为¡A抛°âªº¥t¤@个ì¦]«Ü¥i¯à¬O¥x湾长´Á§ë资ªÌªº¤j¶q抛°â¡F该ªÑ¦b¥x¥_¥æ©ö©Ò¤W¥«¨ì2020¦~7¤ë¡A§ë资ªÌ¦´N¦bµ¥«Ý¤@¨Ç§Q¦n®ø®§¡C¦b¥æ©ö条´Ú¤½¥¬¦Z¡A¤j¶q抛°â¬Æ¦Ü导PªÑɲ¶^¦Ü§C¤_发¦æɲªº25%¡C
³q过www.DeepL.com/Translator¡]§K费ª©¡^½译
After the market closed on March 1st, Aslan announced a $60 MM offering and the stock tanked. The company clearly needed money to fund its Phase 2b study, scheduled to start in the second half of 2021, so the offering should not have come as a huge surprise on the heels of positive data. However, unlike so many recent biotech deals, where a stock has often rallied into the deal, this did not occur.
The sell-off may have been precipitated by an article at Evaluate Vantage entitled: Early data boost Aslan, but don¡¦t ignore the red flags. Author Amy Brown wrote that 2 issues should be of concern to Aslan investors: a) ASLN ¡¦004¡¦s composition of matter expires in 2027 and b) Aslan will owe a considerable amount of money to licensor CSL in the form of milestones and royalties.
Both of these are fair points, but I would respond as follows: a) Carl Firth, Aslan CEO, with whom I spoke twice in the last two weeks, believes that with biologics and other extensions, dosing patents that are already filed and published and the time it takes to prove biosimilarity, the Company may be fine until 2040. b) Next, while the payments to CSL are meaningful, the opportunities for ¡¦004 in AD, asthma and perhaps other indications are large enough such that even if ¡¦004 achieves just $1 BB in sales at peak, less than 10% of expected peak sales for Dupixent, these revenues would provide much upside for the Company.
I believe that another reason for the sell-off was likely substantial selling from long-term investors in Taiwan; the stock had been listed on the Taipei exchange until July 2020 and investors had long awaited some positive news. Massive selling even led the stock lower to 25% below the offering price, after the deal terms were announced.
¨ä¥L½Ð°Ñ¾\¤Wzºô§}
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/3/18 ¤U¤È 09:21:52
²Ä 3977 ½g¦^À³
|
¬Ý¨Ó·à¤l»W¶Õ«Ýµo¤F ªÑ»ù½Ä¤X |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/18 ¤U¤È 07:47:53
²Ä 3976 ½g¦^À³
|
ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-appoints-dr-kathleen-metters-independent
Mar 18,2021
ASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent Director
SINGAPORE, March 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years¡¦ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PXS). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.
Kathleen spent over 20 years at Merck & Co where she held a number of leadership positions, including Senior Vice President and Head of Worldwide Basic Research, with oversight of all the company¡¦s global research projects, and Senior Vice President, External Discovery and Preclinical Sciences. She was also Chair of the Respiratory Worldwide Business Strategy Team, reporting directly to the Chief Executive Officer. Dr Metters holds a BSc in Biochemistry from the University of Manchester Institute for Science and Technology, and a PhD from Imperial College of Science and Technology in London.
Damien Lim, representative of BV Healthcare II Pte Ltd, has transitioned off the board with effect from March 18, 2021, after serving for 10 years.
Andrew Howden, Chairman, ASLAN Pharmaceuticals, said, ¡§We are pleased to welcome Dr Metters to ASLAN¡¦s board of directors and look forward to working with her. Kathleen is an accomplished industry leader who brings extensive scientific acumen and global development expertise in immunology. Her insight and experience, combined with that of Dr Neil Graham who recently joined the board, will provide valuable guidance to the management team as ASLAN advances its clinical programs and its pivot to the US. On behalf of the board, I would like to extend our appreciation to Damien Lim for his significant contributions to the growth of the company over the past decade.¡¨ ·s¥[©Y¡A2021¦~3¤ë18¤é¡]GLOBE NEWSWIRE¡^--专ª`¤_临§É阶¬q§K¬Ì学ªº¥Íª«¨î药¤½¥qASLAN Pharmaceuticals¡]Nasdaq:ASLN¡^ ¤µ¤Ñ«Å¥¬¥ô©RKathleen M. Metters³Õ¤h为独¥ß¸³¨Æ¡C
Metters³Õ¤h¦b发现©M开发¥Î¤_ªv疗ºC©Ê¯e¯f¡]¥]¬A¦Û¨§K¬Ì©Ê¯e¯f¡^ªº·s«¬疗ªk¤è±拥¦³30¦h¦~ªº经验¡C
Metters³Õ¤h¬O¦h个¸³¨Æ会ªº¦¨员¡A¥]¬AHemoshear Therapeutics LLC©MPharmaxis Ltd¡]ASX:PXS¡^¡C
³Ìªñ¡A¦o¬OLycera¤½¥qªºº®u执¦æ©x©M总µô¡A¦b¨º¨½¡A¦o领导¤F¤@个强¤jªº专§Q©M¦X§@§K¬Ì调节剂项¥ØªººÞ¹D¡C
Kathleen¦bÀq§J¤½¥q¤u§@¤F20¦h¦~¡A担¥ô过¦h个领导职务¡A¥]¬A°ª级°Æ总µôÝ¥þ²y°ò础¬ã¨s¥DºÞ¡A负责监·þ¤½¥q©Ò¦³ªº¥þ²y¬ã¨s项¥Ø¡A¥H¤Î¥~³¡发现©M临§É«e¬ì学°ª级°Æ总µô¡C ¦o还´¿担¥ô©I§l¨t统¥þ²y业务战²¤团队¥D®u¡Aª½±µ¦Vº®u执¦æ©x报§i¡CMetters³Õ¤h拥¦³°Ò彻´µ¯S¤j学¬ì§Þ学°|¥Íª«¤Æ学学¤h学¦ì©M伦´°«Ò国²z¤u学°|ªº³Õ¤h学¦ì¡C
BV Healthcare II Pte Ltdªº¥NªíDamien Lim¦b¥ô职10¦~¦Z¡A¤_2021¦~3¤ë18¤é°h¥X¸³¨Æ会¡C
ASLAN¨î药¤½¥q¸³¨Æ长Andrew Howdenªí¥Ü¡G
§Ú们«Ü°ª兴欢ªïMetters³Õ¤h¥[¤JASLAN¸³¨Æ会¡A¦}´Á«ÝÉO¦o¦X§@¡C Kathleen¬O¤@¦ì¨ô¦³¦¨´Nªº¦æ业领³S¡A¦o带来¤F§K¬Ì学领°ì广ªxªº¬ì学头脑©M¥þ²y开发ªº专业ª¾识¡C¦oªº¬}¹î¤O©M经验¡A¥[¤W³Ìªñ¥[¤J¸³¨Æ会ªºNeil Graham³Õ¤h¡A 将¦bASLAN±À进临§É项¥Ø©M¦V¬ü国转²¾ªº过µ{¤¤为ºÞ²z团队´£¨Ñ宝贵ªº«ü导¡C
§Ú谨¥Nªí¸³¨Æ会¦VDamien Limªí¥Ü·P谢¡A·P谢¥L¦b过¥h¤Q¦~¤¤为¤½¥qªº发®i°µ¥Xªº«¤j贡献¡C
³q过www.DeepL.com/Translator¡]§K费ª©¡^½译 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/18 ¤U¤È 07:11:20
²Ä 3975 ½g¦^À³
|
03/17/21 H.C. Wainwright Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm¡¦s price target on Aslan Pharmaceuticals to $8 from $5 and keeps a Buy rating on the shares. ASLAN004 achieved impressive reduction in eczema severity, Chen tells investors in a research note.
Read more at: thefly.com/n.php?id=3267851
H.C.¡]Wainwright¡^¤ÀªR®vYi Chen±N¤½¥q¹ïAslan Pharmaceuticalsªº¥Ø¼Ð»ù®æ±q5¬ü¤¸´£°ª¦Ü8¬ü¤¸¡A¨Ãºû«ù¹ï¸ÓªÑªº¶R¤Jµû¯Å¡C
Chen¦b¤@¥÷¬ã¨s³ø§i¤¤§i¶D§ë¸êªÌ¡AASLAN004ªºÀã¯lÄY«µ{«×±o¨ì¤F¡§¥O¤H¦L¶H²`¨è¡¨ªº´î¤Ö¡C
¦b¥H¤U¦ì¸m¤F¸Ñ§ó¦h«H®§¡G
thefly.com/n.php?id=3267851
--------------------- 03/07/21
Read more at: thefly.com/n.php?id=3261587 Aslan Pharmaceuticals price target lowered to $9 from $10 at Piper Sandler Piper Sandler analyst Edward Tenthoff lowered the firm¡¦s price target on Aslan Pharmaceuticals to $9 from $10 and reiterates an Overweight rating on the shares. The analyst trimmed the target to account for dilution from the 15M share offering.
Read more at: thefly.com/n.php?id=3261587
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/3/18 ¤U¤È 06:22:47
²Ä 3974 ½g¦^À³
|
¾÷ºcªk¤H½Õ¤É¥Ø¼Ð»ù¨ì8¤¸~
www.benzinga.com/stock/asln/ratings |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/3/17 ¤U¤È 10:24:39
²Ä 3973 ½g¦^À³
|
ÁÈ¿úúµ|¡A¤Ñ¸g¦a¸q
§Ú·|§Ö§â¿úÂà¦^¨Ó¡A¦A§ä¦n¼ÐªºÂ½¨â½... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/17 ¤U¤È 10:11:04
²Ä 3972 ½g¦^À³
|
1 10000ªÑ¥H¤U¤pªÑªF®Ú¥»¦©¤£¨ìµ|ªÑ ©Î¥u»Ýú¤Ö³\ªºµ| ( °²³]¥¼Âà´««e¦¨¥»5¬ü¤¸ ¨CªÑº¦¨ì30¬ü¤¸¤@¦¸½æ¥X )
2 10000¨ì30000ªÑ¤À2-3¦~½æ¥X¤]¤£©ö¦©¨ìµ|©Î¥u»Ýú¤Ö³\ªºµ|(°²³]¥¼Âà´««e¦¨¥»5¬ü¤¸ ¨CªÑº¦¨ì30¬ü¤¸)
3 ¨CªÑº¦¨ì30¬ü¤¸³Q¦©µ|¤£¬O«Ü¦n¶ý ? «ÂI¤£¬Oµ|, ¬O·|¤£·|º¦
§A³ßÅwªÑ²¼¤£º¦¦©¤£¨ìµ| , ÁÙ¬O³ßÅwªÑ²¼¤jº¦³Q¦©¤@¨Çµ| ?
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤M¬Í¦Ñ¥|10139802 |
µoªí®É¶¡:2021/3/17 ¤U¤È 02:37:23
²Ä 3971 ½g¦^À³
|
·íªì¨È·à±dÂà´«ADR®É¡A¦³¥Ó³ø¦¨¥»¡A°êµ|§½¨ºÃäÀ³¸Ó¦³¸ê®Æ¡C °²³]¨È·à±d¥¼¨Ó°ª»ù³Q¨ÖÁÊ¡A¥Î°ê¤º½Æ©e°UªºªÑªF¡AÅK©w¶]¤£±¼¡Anúµ|¡A Y°êµ|§½¥h²M¬d¡A¨ä¸ê®Æ®w¤º¡A·íªì¦³Âà´«ADR¡A¥Ø«e¥¼¥Ó³øªºªÑªF²M³æ¡A ¨º¥H®ü¥~¨é°Ó«ù¦³¡A¤]¬Onúµ|¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2021/3/17 ¤U¤È 02:36:35
²Ä 3970 ½g¦^À³
|
¤£ª¾Y¨È·à±d³Q¨ÖÁÊ«á,©Ò±oªº¬üª÷¶W¹L¥x¹ô6¦Ê¦h¸U³¡¥÷(¦©°£¦¨¥»),¤£ºÞ¦³¨S¦³¶×¦^¥xÆW¬On³Q¦©20%ªºµ|,ÁÙ¬O ¦³¶×¦^¥xÆW¶W¹L¶W¹L¥x¹ô6¦Ê¦h¸U³¡¥÷¤~n¦©µ|,¦pªG¬O«áªÌ¨º´N¨C¦~¶×¤Ö©ó¥x¹ô6¦Ê¦h¸U´N¦n¤F
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤jGE10145523 |
µoªí®É¶¡:2021/3/17 ¤U¤È 02:18:38
²Ä 3969 ½g¦^À³
|
¥Î®ü¥~¨é°Ó´N¬O¦pªGÁÈ¿ú¤F¡C´N§ï¶R¦¨ETF¦¬®§¡C ¦A§âETF ¤@¼ËÂà¦^¥xÆW½Æ©e°U¡C¤£½æ¤@ª½»â®§´N¦n¡C ¤£·|¦]¬°§Ú½æ¤F¨È·à±dÁÈ¿ú´Nnúµ| ¯Ê¿ú®É½æ¤@¨Ç¡C¤@¦~¤£n½æ¶W¹L670¸U´N¦n¡C ¦pªG¨È·à±d¯uªºÅý§Ú°]´I¦Û¥Ñ¤F¡A³o¼Ë¤~¯à§â¸ê²£¤@ª½¯d¤U¨Óªü¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/3/17 ¤U¤È 02:01:08
²Ä 3968 ½g¦^À³
|
20%À³¸Ó¬O¦©°£670¸U ¶W¥Xªº¤~¦©20%
§Ú¤]¬O½Æ©e°U §Úªº¨é°Ó·íªì³Ì«á§iª¾§Ú ¥L̤½¥q³Ì«á¨M©wÂà´««áªº¦¨¥» ¬O¥H³Ì«á¤@¤Ñªº¦¬½L»ù.., |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/17 ¤U¤È 01:16:39
²Ä 3967 ½g¦^À³
|
¥Ø«e¨È·à±d¤½¥qªº³Q¨ÖÁÊ»ùȦôp:
©ú¦~©³°µ§¹(2022¦~©³) ASLAN004 AD 2b Á{§É¡Ï ý³Ý 1b Á{§É ¡Ï ASLAN003 MS 2a Á{§É
¼ç¦b³Q¨ÖÁʲ{ª÷¥«È¦ô: 30e¬ü¤¸¡]¥Ø«eAslan004 §é²{È)¡Ï3e¬ü¤¸§é²{¼WÈ¡Ï4e¬ü¤¸2b°µ§¹¼WÈ ¡Ï5e¬ü¤¸/aslan003=42»õ¬ü¤¸¡X-
ASLAN004 ³Ì°ª¾P°â 60»õ¬ü¤¸ ASLAN003 ³Ì°ª¾P°â10»õ¬ü¤¸ ¡X¡X¡X- 42»õ¬ü¤¸/70,000¤dªÑADR = 50¬ü¤¸-ADR
¨CªÑADR ¼ç¦b³Q¨ÖÁÊ»ùÈ 50¬ü¤¸( 2022¦~©³)
¡X¡X¡X¡X¡X¡X
¥t¨ÖÁʪ̶·¤ä¥I ¤W´åCSL/Aslan004¤Î Almirall/Aslan003ªº¶RÂ_ ¦X¬ù ±ø¥óªºª÷ÃB¡C CSL ¦ô17»õ¬ü¤¸ªº²{È(2022¦~©³) Al,irall ¦ô 2.5»õ¬ü¤¸ªº²{È¡]2022¦~©³) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§ë¸ê¬ö«ß10145266 |
µoªí®É¶¡:2021/3/17 ¤U¤È 01:02:55
²Ä 3966 ½g¦^À³
|
¸Ø±i¤j
¯àú³o»ò¦hµ|¤]¬O¶}¤ßªº¤@¥ó¨Æ
©ñ¼e¤ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/3/17 ¤U¤È 12:49:12
²Ä 3965 ½g¦^À³
|
«Ó°¶¤j
°²¦p¦p¤Ñ©R¤j©Ò»¡,«ù¨È·à±dADR25000ªÑ,¤§«á¥HADR¨CªÑ80¤¸³Q¨ÖÁÊ,
25000*80*28¶×²v=5600¸U, 5600¸U*20%=1120¸U~~~~~~~¬Ý¨Ó.¯uªº¬O¦©©w¤F. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/17 ¤U¤È 12:44:35
²Ä 3964 ½g¦^À³
|
¥Î®ü¥~¨é°Ó¨ä¹ê¤]¨S¥Î ¥¦¥u¬O¤£¹³¥xÆW½Æ©e°U·|¥D°Ê¦V°êµ|§½¥Ó³ø ©Ò¥H°£«D§A¿ú¤@ª½©ñ¦b®ü¥~±b¤á³£¤£¶×¦^¥xÆW ¤£µM¶×¦^¨Ó®É°êµ|§½¤@¼Ë·|¦³¸ê®Æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/3/17 ¤U¤È 12:32:07
²Ä 3963 ½g¦^À³
|
¶W¹L¤@©w¼ÆÃB »Ýn¦©20%ªº¹Ò¥~©Ò±o????
°²¦p¦p¤Ñ©R¤j©Ò»¡,«ù¨È·à±dADR25000ªÑ,¤§«á¥HADR¨CªÑ80¤¸³Q¨ÖÁÊ,
25000*80*28¶×²v=5600¸U, 5600¸U*20%=1120¸Un³Qúµ|,¤Ñ°Ú,
¦³¨ä¥L¸`µ|¤è¦¡¶Ü??½Ð±Ð¦U¦ì¤j¤j. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§ë¸ê¬ö«ß10145266 |
µoªí®É¶¡:2021/3/17 ¤U¤È 12:09:56
²Ä 3962 ½g¦^À³
|
¤£·|...
¨é°ÓÀ°Âà´«¬°¬üªÑ®É¶·¶ñ¤J§ë¸ê¦¨¥»
§Úªº¨é°ÓÁÙn§Ú¦Û¤vºâµ¹¥L¥Ó³ø... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/17 ¤W¤È 11:51:35
²Ä 3961 ½g¦^À³
|
ÁȶW¹Lµ¥È670¸U¥x¹ô´Nn¦©µ|¤F ¬ðµM·Q¨ì¦pªG§Ú̬OÂà´«¹L¥hªº °êµ|§½¨ºÃäÅã¥Üªº¦¨¥»¸Ó¤£·|¬O0¡A³o¼Ë¤j¤á·d¤£¦n½ß¿úÁÙn³Q¦©µ| |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkim10134548 |
µoªí®É¶¡:2021/3/17 ¤W¤È 09:57:15
²Ä 3960 ½g¦^À³
|
¬üªÑ¥æ©öªº·s¤â½Ð°Ý ¤jGE ¦pªG¥Îfirsttradeªº±b¤á¡A¥æ©ö¦w¥þ¶Ü ? ¥Îfirsttradeªº±b¤á½æ¥X©Ò±o¡A¥i¥H¤£¥Ó³ø¹Ò¥~©Ò±o¶Ü ?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤jGE10145523 |
µoªí®É¶¡:2021/3/17 ¤W¤È 09:10:04
²Ä 3959 ½g¦^À³
|
¦b³oùبü¯q¨}¦h ¦^õX¤@ÂIÂI¨Æ±¡µ¹¤j®a ¦pªG¥Ø«e¬O¥Î½Æ©e°U«ù¦³¨È·à±dªºªB¤Í ¤§«á¦pªG¤jº¦«Ü¦h¿½æ¥X ¥i¯à·|»Ýn¥Ó³ø¹Ò¥~©Ò±o ¶W¹L¤@©w¼ÆÃB »Ýn¦©20%ªº¹Ò¥~©Ò±o
§Ú¥»¨Ó¬O¥Î¸s¯q½Æ©e°U«ù¦³¨È·à±d ¦]¬°¤w¸g¨â¸UªÑ¤F ¤£·Q½æ¥Xn°ªÃB¤âÄò¶O¸ò¥¼¨Ó¥i¯à税ª÷ ©Ò¥H§Ú¤S¥h¶}¤Ffirsttradeªº±b¤á ±µ¤U¨Ó´N¥h¶ñªí®æ dct§âªÑ²¼±q¸s¯qÂà¨ìfirsttrade«ù¦³ ¥¼¨Ó½æ¥X °£«Dn¤@¦¸Âà¦^¥xÆW ¤£µM¤£·|¦³µ|ª÷
¶ñªí®æªº¤è¦¡ ¬O¨âÃä¨é°Ó¦U¦³¤@Óªí®æn¼g ¸s¯q¥h§ä·~°Èû´N¥i¥H Firsttrade«h¬Oºô¸ô¤U¸ü«á¼g¦n¤W¶Ç ¤j¬ù7-10¤Ñ´N¦¨¥\Âà¥X ¸s¯qªº½Æ©e°U·|±q½Æ©e°U«ùª÷±b¸¹¦©100¬üª÷ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/15 ¤W¤È 09:35:09
²Ä 3958 ½g¦^À³
|
预p¤µ¦~²Ä¤G©u¡AFDA®Öã ADÃĵýªº Tralokinumab.
2019/12 ,³q¹L¤T´ÁÁ{§Éªºtralokinumab,--- IGA 0/1 was 19.1% with active therapy versus 8.1% with placebo (P < .001) in ECZTRA 1 24.0% versus 12.4% (P < .001) in ECZTRA 2. For
EASI 75, the respective proportions were 33.4% versus 17.3% (P< .01) and 37.9% versus 16.4% (P < .01).
¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 1b ´Á¤¤ EASI-75 400mg/600mg ¡A组¥i¹F67%(8¶gªvÀø)¡C ¯uªº®t¤@¿¡A©Ò¥H»¡ASLAN004 ¨úADÃĵý¡A¤Q®³¤QáC
200mg组¤]¦³50%¹FEASI-75,
¹ï·Ó组0%
¦]¬°Tralokinumabªº¾÷Âà¡AµLªkªý断¤uL4°T¸¹¶Ç»¼¡C
¦ÓASLAN004¥i¦P®Éªý断IL4¤ÎIL13°T¸¹¶Ç»¼¡C ¬GÀø®Ä½¿©óTralokinumab
LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis Submission includes data from pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 studies evaluating safety and efficacy of tralokinumab
July 09, 2020 08:00 AM Eastern Daylight Time BALLERUP, Denmark, & MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced that the Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) has been accepted for review by the U.S. Food and Drug Administration (FDA). The acceptance of the BLA is the beginning of the formal review procedure for this potential new treatment by the FDA. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date in the second quarter of 2021. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/14 ¤U¤È 07:42:41
²Ä 3957 ½g¦^À³
|
ASLAN004 1b(8¶gªvÀø)´Á¤¤¸Ñª¼ ¥¼¨ÓAD¤T´Á¥Dn«ü¼Ð¤§¤@ EASI-75
400mg/600mg 67% 200mg 50% ¹ï·Ó组为0%
Dupilumab 3 ´Á¡A¨C¶g¤@°wx16¶g EASI-75 50%
¥HÀø®Ä¡A¤Î¦w¥þ©Ê ¦Ó¨¥¡AASLAN004 ADÃÄÃÒ¡A¯uªº¤Q®³¤QáC
¦A¨Ó2b/3´ÁÁ{§É¡A测¸Õ¦b³Ì¨ÎÀø®Ä¤U¡A³Ì¤Öªº¥´°w频²v¤Î³Ì¨Î¾¯¶q¡C
¥Ñ©ó²Ä0/2¶g¡A°ª¾¯¶q¡A¬O¬Û·í«nªº³]p¡C Dupilumab 600mg°_©l¶q¡C¨ä¥L300mg,16¶g¡A¦Xp2700mg Lebrikzumab 500mg,¤À§O¦b²ÄO¡A2¶g¡A¨ä¥L250mg,16¶g¡A¦Xp¡A2500mg
ASLAN004 0/2¶g¡A600mg,¨ä¥L¤G¶g¤@°wx200mg,16¶g¡A2400mg
«Ü¥i¯à¬O¥¼¨Ó¥D¤O¤§¤@¡C
¥t¥~¥|¶g¤@针¡Ax600mg,¦Xp2400mg ¡A¥ç¥i¯à¦¨¥\¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/3/13 ¤U¤È 02:42:32
²Ä 3956 ½g¦^À³
|
¹j¾À¥_·¥¬Pªº²´²\ ´Â¦V¥_·¥¥úÁÚ¶i¤F
·à¤l¤]n¥[ªo¤X ®³¥X¸Ó¦³ªº¹ê¤O ¤j¤Oªº«ã§q§a
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/13 ¤W¤È 08:37:55
²Ä 3955 ½g¦^À³
|
関©óASLAN004ªº2b Á{§É³]p
0,2,4,8,12¡A¦@5°wx600mg¡Ñ16¶g¡A¦Xp3000mg,
vS Dupilumab 2¶g¤@°wx300mg¡A°_©l¶q600mg,
¦Xp2700mg,
¥¼¨ÓASLAN004 2bY¦¹³]pªºÀø®Ä¡A¯à¦p1b¡A ESAI-50 88% vs dupilumab 60% EASI -75¹F67% vs dupilumab 50% IGA¡A0/1 ©Ô¤W50% vs dupilumab 38%
¥DnÀø®Ä«ü¼ÐÀu©ó¹ï¤â30%¤Q28%¥¼¹F¤ÏÀ³(EASI-50)/2-2%¦¨¥»®t²§=¦Xp42%
¤]´N¬O»¡¡AASLAN004ªº¸gÀٮįq¡A¶W¹LDupilumab ,·í¦~Àøµ{费¬Û¦P¤§¤U¡C
«OÀI¤½¥qµ´¹ï·|Àu¥ý¨Ï¥ÎASLAN004¡A«h¥¼¨Ó³Ì°ª¾P°â¹F100»õ¬ü¤¸¡A¤£¬O¹Ú¡C
«D±`¦nªº³Q¨ÖÁʼЪº¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/13 ¤W¤È 06:21:19
²Ä 3954 ½g¦^À³
|
II«¬ª¢¯g¡A须¥Íª«»s¾¯¦b¬ü°êªº谮¦b»Ý¨D«D±`¤j¡C
Dupilumab ¥h¦~À禬40»õ¬ü¤¸¡A¬ü°ê¾P°â¦û80%¡C
¦ý¬ü°ê¥«³õªº渗³z²v¡A¤£¨ì10%¡C¡C 2019¦~销23»õ¬ü¤¸¡A¤½¥qºÙ¡A¬ü¥«³õ渗³z²v¤£¨ì5%¡P
¤µ¦~3¤ë1¤é¡A¶i¤J¤¤°êÂå«OBÃþ¡A¨C针300mg费¥Î¦ô14000¤¸¥x¹ô¡A¬O¨Ñ¥xÆW°·«Oªº70%¡A¥ª¥k¡C ¦ý¤H¥Áªº¦Û¥I额¡A¥i¯àn50%¡C(¨C针7000¤¸¥x¹ô)
7000x17°w/¦~¡A=119,000¥x¹ô¦Û¥I额¡C
³o负¾á¥i¯à约«e7000¸U¤H¡A¥i¥Xªº°_¡A
7000¸U¤H/13»õ¤H=约5.3%¡A
¤H¤f¤ñ¨Ò约¬ü°ê80%¦³«OÀI3.3¡Ñ80%=2.6»õ¤H
7000¸U¤H/2.6»õx50%(³æ»ù约¬ü°ê°50%) =13.5% (¤¤°êªºÀ禬¥i¯à¬°¬ü°ê1/7) ROCHEªº¸~½FÀù¯gÃÄ20-30ºØ¡A¤¤°êÀ禬¡A¦û11%¡C
www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/20200611_Dupixent_call_FINAL.pdf?la=en&hash=D80AF8E4B5DA6A9A9ED74F9E34B03251
ÁÉ¿Õµá 2020/06/11 Dupilumab ¶}µop¹º ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/10/9 ¤W¤È 11:34:13²Ä 44 ½g¦^À³ Dupilumab ¬ü°ê¥Ø¼Ð¥«³õ¶}µop¹º¡]¸ê®Æ¨Ó·½ : ÁÉ¿Õµá 2020/06/11)
202¦~ 6¤ë11¤é¡AÁÉ¿Õµá¦b§ë¸ê¤HR&D¶}©ñ¤é¤W®i¥Ü¤FDupixentªº¥¼¨Ó¶}µop¹º¡AåªR¤FDupixentªº¼Wªø¾÷·|©M¦b2«¬ª¢¯g¯e¯f¤¤ªº¶}µoµ¦²¤¡A´¦¥Ü¤F¹ïDupixent©ê¦³100»õ¼Ú¤¸¾P°â®pȹw´Áªºì¦]
¤@¡BÁɿյᴣ¨Ñªº¬y¦æ¯f¼Æ¾Ú¨Ó¬Ý¡A¬ü°ê²Å¦X¥Íª«»s«~ªvÀø«ü¼x¡]¤£¥i±±AD) ªº ¦¨¤H¯SÀ³©Ê¥Öª¢±wªÌ¤j¬ù¦³170¸U¤H¡A 12-17·³«C¤Ö¦~¦³40¸U¤H¡A 6-11·³¨àµ£¦³9¸U¤H¡A 6·³¥H¤U 7.5¸U¤H ¦Xp226.5¸U¤H ¦ÓDupixent¦b³o³¡¤À¤H¸s¤¤ªº¥«³õº¯³z²vÁÙ¤£¨¬5%¡A¨ã¦³«D±`¤jªºÂX±iªÅ¶¡¡C
Dupixent¬O¬ü°ê§åã¤W¥«ªººÓªvÀø¯SÀ³©Ê¥Öª¢ªº¥Íª«»s¾¯¡A¾A¥Î¤H¸sªº¦~ÄÖ¤£Â_©Ý¼e¡A¥Ø«e¤wÀò§å¥Î©ó¦¨¤H¡]2017¦~3¤ë¡^¡B12-17·³«C¤Ö¦~¡]2019¦~3¤ë¡^©M6-11·³¨àµ£¡]2020¦~5¤ë¡^¡C¥t¥~¡A°w¹ï6Ó¤ë~5·³¯SÀ³©Ê¥Öª¢±wªÌªºÁ{§É¸ÕÅç¤w¶i®i¦ÜII/III´Á¶¥¬q¡C
¤G¡B¤¤¡B««×ý³Ý ¬ü°ê ¥Ø¼Ð¥«³õ97.5¸U¤H¡X¡X-2018¦~¤w¨ú±oÃÄÃÒ
¤T¡AºC©Ê»ó-»ó窦ª¢¦ñ»ó®§¦×(CRSwNP ¬ü°ê¥Ø¼Ð¥«³õ 9¸U¤H¡X-2019 ¤w¨ú±oÃÄÃÒ
«ö·ÓÁɿյ᪺¶}µop¹ºªí¡ADupixent¦b¹L¥h3¦~¤w¸g¦³¯SÀ³©Ê¥Öª¢¡Bý³Ý¡BºC©Ê»ó-»óÄuª¢¦ñ»ó®§¦×¤T¤j¾AÀ³¯gÀò§å¡A¦b¬ü°ê¥«³õªº¥Ø¼Ð¨ü²³¤H¸s¤w¸g¹F¨ì336¸U¡C
¥¼¨Ó3¦~Dupixent¹wpÁÙ±N³°Äò±ÙÀòµ²¸`©ÊÄo¯l¡]PN¡^¡B¶Ý»Ä©Ê²ÓM©Ê¹ºÞª¢¡]EoE¡^¡BºC©ÊëC³Â¯l¡]CSU¡^¡B¤j¯p©ÊÃþ¤Ñ¯p½H¡B2«¬ª¢¯gCOPDµ¥·sªº¾AÀ³¯g¡A¦b¬ü°ê¥«³õ²Å¦X¥Íª«»s«~ªvÀø«ü¼xªº¼W¶q±wªÌ¸sÅéÁÙ¦³75¸U¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/13 ¤W¤È 01:40:18
²Ä 3953 ½g¦^À³
|
2019/12 ,³q¹L¤T´ÁÁ{§Éªºtralokinumab,--- IGA 0/1 was 19.1% with active therapy versus 8.1% with placebo (P < .001) in ECZTRA 1 24.0% versus 12.4% (P < .001) in ECZTRA 2. For
EASI 75, the respective proportions were 33.4% versus 17.3% (P< .01) and 37.9% versus 16.4% (P < .01). ¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 2b ´Á¤¤ EASI-75 400/600ng ¡A组¥i¹F67%(8¶gªvÀø)¡C ¯uªº®t¤@¿¡A
¦]¬°Tralokinumabªº¾÷Âà¡AµLªkªý断¤uL4°T¸¹¶Ç»¼¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/13 ¤W¤È 12:01:16
²Ä 3952 ½g¦^À³
|
Dupilumab»PASLAN004 ³£¬OÂùÂê©w¨üÅéIL13»PIL4¡A ¨ä¥L¬ãµoªºÃĪ«¤j³£Âê©w°tÅéLigand Âê©w¨üÅé»PÂê©w°tÅéÀø®Ä¨ì©³®t¶Z¦³¦h¤j? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/12 ¤U¤È 11:17:08
²Ä 3951 ½g¦^À³
|
¥xÁÞ¤j,
𠃊ebrikizumab ¦bROCHE¤â¤W®É¡Aý³Ý¤T´ÁÁ{§É¡BCOPP¤T´ÁÁ{§É ¡A¥Dn«ü¼Ð¬Ò¥¼¹F¼Ð¡AP> 0.05
¨È·à¤½¥q¡A²¤¶¥i¬O¸¹ºÙ AD¤Îý³Ý¡A³Ì¨ÎÀøªk¡A¨ä¥LCOPD ... II«¬ª¢¯g¡A¸gDupilumab ÅçÃÒ¹LªÌªº¤j¾AÀ³¯g¡A¥¼¨ÓAS𠃊AN004 ¬Ò·|¶}µo¡A¶i¤J¤HÅéÁ{§É¡C
»ùÈ°ª¦h¤Ö! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/12 ¤U¤È 11:04:25
²Ä 3950 ½g¦^À³
|
¤Ñ©R¤j Lebrikizumab ¦³³oºØ±ÂÅv¨ÖÁÊ»ù½X, ¬Ý§¹ASLAN004´Á¤¤¼Æ¾Ú¤j®aÀ³¸Ó§ó¦³«H¤ß
Lebrikizumab Dupilumab ³£¬OÆ[¹î¨ì16¶gªºÀø®Ä ASLAN004´Á¤¤¼Æ¾Ú«üÆ[¹î8¶g , ¤Gb ¼Æ¾ÚÆ[¹îÀ³·|¤ñ·Ó¨ì16¶g |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/12 ¤U¤È 11:04:03
²Ä 3949 ½g¦^À³
|
§¨Ó2019¦~12 ¤ë ,©MDermira ¤½¥q¹F¦¨¨óij¡A¨Ã¤½¥¬¨ÖÁʱø¥ó®É¥«³õ¹ïDupilumab ³Ì°ª¾P°â¦ô60»õ¬ü¤¸¡C
2019¦~12¤ë¡AREGNªºCE〇 «Å¥¬¡A¥¼¨ÓDupilumab ³Ì°ª¾P°â¦ôp¹F 100»õ¼Ú¤¸¡C
Y¤µ¤Ñ2021¦~3¤ë¡A§¨Ó¤~¨ÖÁÊDermira , ¥i¯àn¦hªá¤@¿¿ú¡A¬ù22»õ¬ü¤¸¡A¤~¯à¶R¤U¡C
¥u¯à説§¨Ó¤½¥qªº¸gÀç¹Î¶¤¯uªº¼F®`¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/12 ¤U¤È 10:46:04
²Ä 3948 ½g¦^À³
|
Dermira 2017,08/08 ¦VR0CHE ¨ú±o𠃊ebrikizumab AD±ÂÅv¡A¥u°µ AD 2b Á{§É ¤§«á2020¦~¤¸¤ë³Q§¨Ó¤½¥q¨ÖÁÊ¡C
¡X¡X¡X¡X¡X¡X¡X¡X 2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
Âê©wIL13 °tÅ餧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.1 , 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
2020¦~¤¸¤ë ¦PMOAªº¨ÖÁʧé²{»ùÈ 29»õ¬ü¤¸. 2020/01 §¨Ó¨ÖÁÊDermira ¤½¥q
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 11»õ¬ü¤¸+18»õ¬ü¤¸=29»õ¬ü¤¸,
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/12 ¤U¤È 10:39:10
²Ä 3947 ½g¦^À³
|
1 ´N¦¬®×°ò·ÇÂI¦Ó¨¥ Dupilumab ¹êÅç²ÕIGA4 ¤j¬ù50% ¹ï·Ó²ÕIGA4 ¤j¬ù50% Lebrikizumab ¹êÅç²ÕIGA4 ¤j¬ù30% ¹ï·Ó²ÕIGA4 ¤j¬ù40% ( ¹ï·Ó²ÕIGA4 ¤ñ²v¤ñ¹êÅç²Õ°ª)
Lebrikizumab ¹êÅç²Õ ¦¬®×IGA4 ¤ñ Dupilumab ¤Ö 20% ( Lebrikizumab¤£¬O¦¬¨ì IGA4 «ÜÄY«¯f±w )
2 ´N¦¬®×EASI score Mean °ò·ÇÂI¦Ó¨¥
Dupilumab EASI score Mean : ¹êÅç²Õ±q31.8% --33.2% ¹ï·Ó²Õ33.6% --34.5% Lebrikizumab EASI score Mean : ¹êÅç²Õ25.5% ¹ï·Ó²Õ28.9 %
EASI score Mean ¨âÃÄ®t²§7 % ( ¹êÅç²Õ) 5.1% ( ¹ï·Ó²Õ)
¥u¬O¤@Ó¤G´Á ¤@Ó¤T´Á ¦¬®×¤H¼Æ¤£¦P °ò·ÇÂI¤£¦P «ÜÃøºë½T¤ñ¸û ¥u¯à»¡ªì¨B¬Ý°_¨Ó Lebrikizumab ÁÙ¤£¨¬¥H«Â¯Ù Dupilumab ±ÂÅv ¨ÖÁÊ»ù½X ¬ÝÀø®Ä »P¦w¥þ©Ê Àø®Ä »P¦w¥þ©ÊµLªk¥XÃþ©ÞµÑ, ±ÂÅv ¨ÖÁÊ»ù½X¤]¤£·|¤Ó¦n ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/12 ¤W¤È 08:12:02
²Ä 3946 ½g¦^À³
|
Lebrikizumab²¥v 2020¦~¤¸¤ë ,§¨Ó§¹¦¨¨ÖÁÊDermir ¤½¥q/Lebrikizumab 2019¦~12¤ë¡A§¨Ó«Å11»õ¬ü¤¸¥¬¨ÖÁÊDermir ¤½¥q 2019¦~10¤ë¡ALebrikizumab ¶}©l¤T´ÁADÁ{§É 2019¦~4¤ë¡A¤½¶}¥«³õ¶Ò资约3¦h»õ¬ü¤¸¡A¥«È约8»õ¬ü¤¸¡C 2019¦~3¤ë¡A¤½¥¬Lebrikizumab 2 b.ADÁ{§É¥¿¦Vµ²ªG 2019¦~2¤ë¡A±ÂÅvLebrikizumab欧¬w区¾P±ÂÅv 2018¦~¤¸¤ë¡A¶}©lLebrikiumab 2bÁ{§É 2017¦~8¤ë¡ADermir¦VROCHE¨ú±oLebrikizumab AD±Â¤@Åv¡C
2017¦~ ROCHE Lebrikizumab ¤T´Áý³Ý¤G¤jÁ{§É¡A¨ä¤¤¤@Ó¥¼¹F¥Dn«ü¼Ð¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/11 ¤U¤È 06:41:22
²Ä 3945 ½g¦^À³
|
½÷·ç³oÓ3´ÁÃĪ«,¨C¤é¤fªAJanus kinase 1 (JAK1) inhibitor, JAK1§í¨î¾¯ ³Ì¤jªº°ÝÃD¦b¬r©Ê.
¥«³õ¦ô¦³15»õ¬ü¤¸ªº¤fªA¥«³õ,¤é«á¬ODUPILUMAB ¥ÎµL®Ä«áªº¤G½u¥ÎÃÄ.
www.pfizer.com/news/press-release/press-release-detail/complete-results-second-pivotal-monotherapy-study |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/11 ¤U¤È 06:23:16
²Ä 3944 ½g¦^À³
|
¤j®a¥i¥H¬Ý½÷·ç³oÓ3´ÁÃĪ« www.pfizer.com/news/press-release/press-release-detail/complete-results-second-pivotal-monotherapy-study JADE MONO-2 --> EASI-90 37.7% ASLAN004 --> EASI-90 56% ¤ñ¸û°ò·ÇÂI©Î³\¤£¤Ó¤@¼Ë ! ¦ý¼Æ¾Ú·|»¡¸Ü¨S¦³¨ºÓ®Ä¥Î¬O¤£·|¦³³oÓ56%¼Æ¾Ú¥X²{ªº.... ªÑ»ù²×¨s·|¤ÏÀ³!ÁÙ¬O¨º¥y¸Ü,¨S¦³©ê¨c§A·¥¦³¥i¯à¥¢¥h¦¹¥Í¤§¤¤ °]´I¦Û¥Ñ ªº¾÷·| ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/11 ¤U¤È 05:16:50
²Ä 3943 ½g¦^À³
|
¤j®a¥i¥H¬Ý¤@¤U20210301µo§GªºÂ²³øÀÉ®× ! 쪩¬O^¤åª© ! ¥H¤U³sµ²¤w§ï¦¨¤¤¤åª© www.sendspace.com/file/zqsdco |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/11 ¤U¤È 04:02:16
²Ä 3942 ½g¦^À³
|
¸Ø±i¤j ¦b§Úªº»{ª¾¸ÌASLAN004 ¨S¦³¤T´ÁÁ{§Éªº°ÝÃD,§Ú¥H«e¤w¸g»¡¹L¤F
¹ï¤@®a¤p¥Í§Þ¤½¥q¨Ó»¡ ,¤@ÁûÃÄÁÙn¦Û¤v°µ¤T´Á ªí¬O¨S¤Hn, ¦³¼ç¤OªºÃĤ@ ¤G´Á´N³Q°ù¨«¤F (¨ÖÁʩαÂÅv³£¦³¥i¯à)
¥u¤À¨É¨ì³o¸Ì ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/11 ¤U¤È 03:56:13
²Ä 3941 ½g¦^À³
|
·à¤l³Ìªñ°·Å¤U¨Ó¤F ¤j®an@¤ßµ¥5¤ë´Á¤¤¼Æ¾Ú¤~¦³¾÷·|¦Aµo°Ê ³Ìªñ¥Í§Þ¤½¥q¤£Â_¦³¦n®ø®§ ¹j¾À³Ì®zªº¥_·¥¬P³Ìªñ¤]¤@¸¨R¤Ñ¤F ¥un¼Æ¾Ú°÷¦n¡A·à¤l¤]¯à¤@¼ËÅܶ¯·à |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/3/11 ¤U¤È 03:39:33
²Ä 3940 ½g¦^À³
|
½Ð±Ð¥xÁÞ¤j ·Ó±zªº·N«ä ¨È·à±d¬O·Ç³Æ¦Û¤v°µ¤T´Á¡A¦Û¦æ¾P°â ¹w´Á2026¦~12¤ë ~2027¦~,¤W¥«¾P°â
¤£¨«¨ÖÁÊ?? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/11 ¤U¤È 03:24:09
²Ä 3939 ½g¦^À³
|
¤½¥q2021¦~2¤ë18¤é «Å¥¬¥ô©RNeil GrahamÂå¾Ç³Õ¤h¬°¿W¥ß¸³¨Æ( «ÂI¦p¤U)
1 ³o¦ì§K¬Ì¾Ç©Mª¢¯g¾Ç¤è±ªº±M®a¡A¦b¥þ²yÃĪ«¶}µo©M°Ó·~¤Æ¤è±¾Ö¦³30¦h¦~ªº¸gÅç¡A¯A¤Î¥Ö½§¯f¾Ç¡A·Àã¯f¾Ç¡A¯f¬r¾Ç©MªÍ¯f¾Çªº¦´Á©M±ß´ÁÁ{§É¸ÕÅç¡C
2 Neil Graham³Õ¤h´¿©ó2010¦~¦Ü2020¦~¾á¥ôRegeneron Pharmaceuticals¡AInc.¾Ô²¤p¹º«ü¾É¡A§K¬Ì¾Ç©Mª¢¯g°ÆÁ`µô¡A´Á¶¡¥L³Q¥ô©R¬°dupilumab¶}µop¹º¡]±q²Ä1¶¥¬q¨ì°Ó·~±Ò°Ê¡^ªº¥þ²y¾Ô²¤p¹ºt³d¤H¡C Graham³Õ¤hÁÙ»â¾É¤F°w¹ïÃþ·Àã©ÊÃö¸`ª¢ªºIL-6R§ÜÅéKEVZARA¡]sarilumab¡^©M°w¹ïý³Ý©MCOPDªº§ÜIL33§ÜÅéREGN3500ªº²£«~¶}µo¡C
3 ASLAN Pharmaceuticals¸³¨Æªø¦w¼w¾|•»¨¹y¡]Andrew Howden¡^ªí¥Ü¡G¡§§ÚÌ«Ü°ª¿³ÅwªïNeil Graham³Õ¤h¥[¤JASLAN¸³¨Æ·|¡CÀHµÛ§Ú̱µªñ¤µ¦~ASLAN004©MASLAN003Á{§Éµo®iªº«n¨½µ{¸O¡A¥L¦b§K¬Ì¾Ç©Mª¢¯g¤è±ªº¥þ²y±M·~ª¾ÃÑ¥H¤Î¾Ô²¤«ü¾É±N¹ï§Ú̪º¹Î¶¤¨ã¦³«n»ùÈ
Ó¤H»{¬°ASLAN Pharmaceuticals ·Ç³Æ¦b ASLAN004(AD²§¦ì©Ê¥Ö½§ª¢+Asthma ®ð³Ý) ©M ASLAN003( MS ¦hµo©Êµw¤Æ + RA Ãþ·Àã©ÊÃö¸`ª¢ ) ¤j¤O¶}µo
AD Asthma RA MS ³£¬O¾P°âª÷ÃB«Ü¤j, ¤jÃĤ¤ªº¤jÃÄ
www.christopherreeve.org/zh/international/top-paralysis-topics-in-chinese/multiple-sclerosis
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2021/3/11 ¤U¤È 12:08:34
²Ä 3938 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2021/3/11 ¤W¤È 11:59:34
²Ä 3937 ½g¦^À³
|
¥Ø«eµo¤åªºµJÂI¤j³£¶°¤¤¦b004 003ªº¬ãµo¶iµ{¦n¹³¤ñ004§ó«e±¤@¨Ç ¤w¶i¤J¤G´Á? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/11 ¤W¤È 06:17:57
²Ä 3936 ½g¦^À³
|
¥»¦¸»{ÁÊ5,000¦h¤dªÑ¡A©Ô¤É¥Ø¼Ð»ù¨ì9¬ü¤¸ªº¨é°Ó
预¦ô2021¦~ASLN EPS (0.46) 2022¦~ EPS(0.6) ©ú¦~©³´N·|¿N¥ú²bÈ¡C
©Ò¥H©ú¦~Q3/Q4¡A¥²©w·s¤@½ü¶Ò资 (1)±ÂÅvASLAN004 «D¬ü区ªº¾P°âËC (2)ASLAN004 2b¸Ñª¼¡A¤Î¶Ò资¡C
ASLAN Pharmaceuticals Limited to Post Q1 2021 Earnings of ($0.11) Per Share, Piper Sandler Forecasts (NASDAQ:ASLN) Posted on Wednesday, March 10th, 2021 by MarketBeat
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) - Equities researchers at Piper Sandler increased their Q1 2021 earnings per share (EPS) estimates for ASLAN Pharmaceuticals in a research report issued on Sunday, March 7th. Piper Sandler analyst E. Tenthoff now expects that the company will post earnings per share of ($0.11) for the quarter, up from their prior forecast of ($0.13). Piper Sandler also issued estimates for ASLAN Pharmaceuticals¡¦ Q2 2021 earnings at ($0.10) EPS, Q3 2021 earnings at ($0.12) EPS, Q4 2021 earnings at ($0.13) EPS, FY2021 earnings at ($0.46) EPS, Q1 2022 earnings at ($0.13) EPS, Q2 2022 earnings at ($0.14) EPS, Q3 2022 earnings at ($0.15) EPS, Q4 2022 earnings at ($0.17) EPS and FY2022 earnings at ($0.60) EPS. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/10 ¤U¤È 02:58:06
²Ä 3935 ½g¦^À³
|
¥»½ü¶Ò¸ê¬¡°Ê¬ù1»õ¬ü¤¸¡A²Öpµo¦æªÑ¥»¬ù67,000¤dªÑADR¡Ï¤º³¡奬Ày¬ù7000¤dªÑADR(2014/2017 ¦~¦@ÃB©w3000¤dªÑADR,¥§¡3.7¬ü¤¸¡A©|¥¼»{ÁÊ¡C2020¦~12¤ë(4000¤dªÑ©|¥¼µo¦æ¤Î©w»ù) ¦@74,000ADR.
¥Ñ©ó¨CªÑ²¼±¤w§ï¬°0.05¬ü¤¸¡A ÃB©w¼ç¦b¸ê¥»ÃB= 74,000¤dªÑx0.05¬ü¤¸/ADR=3,700¤d¬ü¤¸ ÃB©w¤wµo¦æ¸ê¥»ÃB=67,000¤dªÑx0.05¬ü¤¸/ADR=3,350¤d¬ü¤¸ ¥»¦¸¶Ò¨ì1»õ¬ü¤¸¡A¦©°£¯Å2400¸U¬ü¤¸ªºt¶Å¡]2020/Q3)¡A²bȬù 7600¸U¬ü¤¸.
²bÈ©M¸ê¥»ÃB¤ñ 7600¸U¬ü¤¸/335¸U¬ü¤¸=¬ù23¿¡X¡X¡X¡X-³o´N¬OÂ÷¶}¥xÆW¡A¥Î¼¯¥§¦è´µì©lªÑµoADRªº¤è«K¡A
¤§«e¥xªÑÃB©wªÑ²¼±ÃB=¨CªÑ10¤¸¥x¹ô, ADR=¥xªÑ5ªÑ=50¤¸¥x¹ô=1.785¬ü¤¸¡X-ÃB©wªÑ²¼±ÃB
¥Ø«eÃB©w¼¯¥§¦è´µªÑ¥»±ÃB=¨CªÑ0.01¬ü¤¸ ADR=5ªÑì©lªÑ=0.ÃB©wªÑ²¼±ÃB |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/10 ¤W¤È 02:57:09
²Ä 3934 ½g¦^À³
|
¦¦bLebrikizumab 2b ADÁ{§É ´N³]p²Ä0¡A2¶gªº«e2°w¡AX500mgªº°w¾¯¶q¡AX ¨C¤G¶g¤@°wx250mg.¡Ñ16 ¶g¡C
¡K¡K¡K¡K¡K¡K
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
pubmed.ncbi.nlm.nih.gov/32101256/
¹Ï¤G ¦³¦U«ü¼Ð,4/8/12/16¶g®É¶¡ªº¤ÏÀ³¤ñ²v |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/3/9 ¤U¤È 04:51:38
²Ä 3933 ½g¦^À³
|
³o´X¤Ñ¯uªº¬O¶^±o ¤£n¤£nªº ¥»¨Ó·Q»¡¯à°÷¦u¦í4³Ì¦n ½Öª¾... ¤Óh¤ß¤F
Ä~Äòµ¥«Ý |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/9 ¤U¤È 02:32:12
²Ä 3932 ½g¦^À³
|
ASLAN004 2b AD¥¼¨Ó³Ì¦³¥i¯à°Ñ¦Ò𠃊ebrikizumab ªº¤T´ÁÁ{§É³]p¡A«e ¤G¦¸SC¥Ö¤Uª`®g¥[«°w¾¯¶q¡A«e¤G°w¤Ó«n¤F·|©Ô¤j¤É¹FEASI 50ªº³t«×¤Î¤ñ²v¡C
(1)ASLAN004 ¤G¶g¤@°w¤§³]p A¡B²Ä0¶g 600mg, ²Ä¤G¶g600mg , ²Ä¥|¡ã14¶g, ¨C¤G¶g¤@°wx200mg , ¦Xp¡A2400mg ¡X¡X¡X³o¬O¥i¯àªº³]p B¡B²Ä0¶g 400mg, ²Ä¤G¶g400mg , ²Ä¥|¡ã14¶g, ¨C¤G¶g¤@°wx200mg , ¦Xp¡A2000mg ¡X¡X¡X³o¬O¥i¯àªº³]p
¡]2)¥|¶g¤@°w 600mgx4=2400mg ¶]¤£±¼
¡X¡X¡X¡X¡X¡X¡X- clinicaltrials.gov/ct2/show/NCT04146363 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) ¤T´ÁAD Á{§É
¤@¡A¹êÅç²Õ °ò½u¤Î ²Ä¤G¶g¡A¦U¥´2°w( 250mg X2=500mg ) , ¤§«á²Ä¥|¶g¡ã¨ì²Ä14¶g¡A¨C¤G¶g¥´¤@°w 250mg ,¦@10°w=2500mg.
ºû«ù´Á ~16~52¶g ¦³¤ÏÀ³ªÌ(EASI ¤@50) ªÌ¡A¨C¤G¶g¤@°w¡A¦@ 19°wx250mgt=4750mg
Experimental: Lebrikizumab Q2W Induction Period (Baseline-Week 16): Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
Maintenance Period (Week 16-Week 52): Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W.
¤G.¹ï·Ó²Õ Placebo Comparator: Placebo Induction Period (Baseline-Week 16): Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14. Maintenance Period (Week 16-Week 52): Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W.
¤T¡A Experimental: Lebrikizumab Q4W Maintenance Period (Week 16-Week 52): Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebikizumab injection.
ºûÅ@¶g´Á¡]²Ä16©P¦Ü²Ä52¶g¡^¡G ±q²Ä16©P¨ì²Ä52¶gªºªvÀø°ò©ó»¤¾É´Á¤¤À³µªªÌªº«·sÀH¾÷¤Æ¡C ¦A¦¸ÀH¾÷¤À²Õ¦ÜLebrikizumab Q4W²Õªº°Ñ»PªÌ¦b¨C¦¸Lebikizumabª`®g«á2¶g±µ¨ü¤@¦¸Lebrikizumab Q4Wª`®g¡A¤@¦¸¦w¼¢¾¯ª`®g¡C
²Ä¥|²Õ
Experimental: Escape Arm (Lebrikizumab Q2W) Maintenance Period (Week 16-Week 52): Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm.
¹êÅç©Ê¡G°k¥ÍÁu¡]Lebrikizumab Q2W¡^ ºûÅ@¶g´Á¡]²Ä16©P¦Ü²Ä52¶g¡^¡G ¦b¤J¾´Á¶¡»Ýn¯SÀ³©Ê¥Öª¢·m±ÏªvÀøªº°Ñ»PªÌ¡A©Î¦b²Ä16©PµL¤ÏÀ³ªº°Ñ»PªÌ¡A±N¦³¸ê®æ¦b°k¥ÍªvÀø«Ç±µ¨üªvÀø¡A°Ñ»PªÌ±N±q²Ä16©P¨ì²Ä52¶g±µ¨ü¶}©ñ¼ÐÅÒªºlebrikizumab Q2W¡C¦¹¥~¡A ¦bºûÅ@´Á¤º¥¼«O«ù¥i±µ¨üªºÅTÀ³¡]EASI¤À¼Æ<°ò½uªº50¢H¡^ªº°Ñ»PªÌ±N¦³¸ê®æ¨Ï¥Î°k¥ÍÁu¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/9 ¤U¤È 02:05:39
²Ä 3931 ½g¦^À³
|
ªÑ»ù¬O»Ýn¾ã²zªº¤£·|¤@ª½Ãzº¦,¥Ø«e³£¯à¼µ¦b3.x¤§¤W,©Î³\¥i¯à¤]·|¶^¨ì2¦rÀY,¦ý³o¥u¬O¹Lµ{¦³@¤ßªºªB¤Í¤@©w¤£·|³Q¬~±¼! ¥Ø«e¤w¸g«ÊµP¤£°Ê,´Á«Ý3Ó¤ë«á1´Á§¹¾ã¼Æ¾Ú¥i¥H±a¨Ó«ç¼ËªºÅå³ß ! ¦U¦ìªB¤Í¤@°_¥[ªo ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/8 ¤W¤È 10:50:41
²Ä 3930 ½g¦^À³
|
ASLN ADR³y¥«
ªÑ²¼¶R¡B½æ µo¦æ¶R¡B½æÅvµý Åvµý¶R¡B½æ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/7 ¤U¤È 06:46:09
²Ä 3929 ½g¦^À³
|
ir.aslanpharma.com/static-files/8374d41f-79f3-4917-b3e4-b146fb668304
s-18
UNDERWRITING Subject to the terms and conditions set forth in the underwriting agreement among us and Jefferies LLC and Piper Sandler & Co. as the representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of ADSs shown opposite its name below:
Underwriter NUMBER OF ADSs Jefferies LLC 7,350,000 Piper Sandler & Co. 5,850,000 H.C. Wainwright & Co., LLC 1,800,000 Total 15,000,000
©Ó¾P(¨óij)
¿í¦u§ÚÌ»PJefferies LLC©MPiper Sandler¡®Co.§@¬°¥Nªíªº©Ó¾P¨óij¤¤³W©wªº±ø´Ú©M±ø¥ó
¤U¦C©Ó¾P°Ó¥H¤Î¥»¦¸µo¦æªºÁp®u½ãïºÞ²z¤H¤¤¡A§Ṳ́w¦P·N¥X°âµ¹©Ó¾P°Ó¡A¨Ã¥B¨CÓ
©Ó¾P°Ó¤w¤À§O¡]¦Ó«D¦@¦P¡^¦P·N±q§Ú̳o¸ÌÁʶR¨ä¦WºÙ¹ï±Åã¥Üªº¬ü°ê¦s°U¾ÌÃÒªº¼Æ¶q¡A¤À§O¦p¤U¡G
Underwriter NUMBER OF ADSs Jefferies LLC 7,350,000 Piper Sandler & Co. 5,850,000 H.C. Wainwright & Co., LLC 1,800,000 Total 15,000,000
===== The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the ADSs as permitted by applicable laws and regulations.
However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion.
Accordingly, no assurance can be given as to the liquidity of the trading market for the ADSs, that you will be able to sell any of the ADSs held by you at a particular time or that the prices that you receive when you sell will be favorable.
©Ó¾P°Ó¤w§iª¾§ÚÌ¡A¦b¥»¦¸µo¦æ§¹¦¨¤§«á¡A¥L̥ثe¥´ºâ¦b¾A¥Îªk«ß©Mªk³W¤¹³\ªº±¡ªp¤U¦bADS¤¤«Ø¥ß¥«³õ¡C
¦ý¬O¡A©Ó¾P°Ó¨S¦³¸q°È³o¼Ë°µ¡A¨Ã¥B©Ó¾P°Ó¥i¥HÀH®É¦Û¦æ¨M©w¤¤¤î¥ô¦ó°µ¥«¬¡°Ê¡A®¤¤£¥t¦æ³qª¾¡C
¦]¦¹¡AµLªk«OÃÒ¬ü°ê¦s°U¾ÌÃÒ¥æ©ö¥«³õªº¬y°Ê©Ê¡A±z±N¯à°÷¦b¯S©w®É¶¡¥X°â±z«ù¦³ªº¥ô¦ó¬ü°ê¦s°U¾ÌÃÒ©Î¥X°â®É¦¬¨ìªº»ù®æ±N¬O¦³§Qªº¡C
The underwriters are offering the ADSs subject to their acceptance of the ADSs from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.
©Ó¾P°Ó´£¨Ñªº¬ü°ê¦s°U¾ÌÃÒn¸g¥Ḻµ¨ü§Ú̪º¬ü°ê¦s°U¾ÌÃÒ¡A¨Ã¦³«Ý¨Æ¥ý¥X°â¡C
©Ó¾P°Ó«O¯d¥H¤UÅv§Q¡G
ºM¦^¡A¨ú®ø©Îקï¦V¤½²³´£¨Ñªº³ø»ù¡A¨Ã¥þ³¡©Î³¡¤À©Úµ´q³æ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/3/7 ¤U¤È 02:21:13
²Ä 3928 ½g¦^À³
|
Aslan Pharmaceuticals Ltd¡]ASLN¡^ªÑ²¼¡G¤ÀªR®v»{¬°±zÀ³¸Ó½æ¥XªÑ²¼¶Ü¡H 2021¦~3¤ë3¤é¡A¬P´Á¤T¡A11¡G54 AM | §ë¸êªÌÆ[¹îû¤ÀªR®v
§ë¸êªÌÆ[¹îûµ¹Aslan Pharmaceuticals Ltd¡]ASLN¡^ªº¤ÀªR®vµû¯Å¬°78¡A³o·N¨ýµÛASLN¦b¤ÀªR®v¤¤ªº±Æ¦W°ª©ó78¢HªºªÑ²¼¡CASLNªº¥§¡¥Ø¼Ð»ù¬°7.5¬ü¤¸¡A¤ÀªR®v±N¸ÓªÑµû¬°±j¤O¶R¤J
reurl.cc/a5dAyX
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/7 ¤W¤È 09:15:03
²Ä 3927 ½g¦^À³
|
12.3 ÃİʾÇ(Dupilumab ¥é³æ) §l¦¬ µ¹¤© dupilumab 600 mg ¥Ö¤Uª`®g (SC)°_©l¾¯¶q«á¤j¬ù 1 ¶g·|¹F¨ì³Ì°ª¥§¡¦å¤¤¿@«× (Cmax) ¡Ó¼Ð·Ç®t(SD)¬° 70.1¡Ó24.1 mcg/mL¡C Dupilumab ¥ý§ë¤©°_©l¾¯¶q 600 mg¡A±µµÛµ¹¤© 300 mg ¨C¶g¤@¦¸(«Øijµ¹ÃÄÀW²vªº 2 ¿)©Î ¹j¶g¤@¦¸¡A¨äéwª¬ºA¿@«×·|¦b²Ä 16 ¶g«e¹F¨ì¡Cºî¦XÁ{§É¸ÕÅçµ²ªG¡A300 mg ¨C 2 ¶gµ¹ÃÄ ¤@¦¸ªºÃ©wª¬ºA³Ì§C¥§¡¿@«×¡Ó¼Ð·Ç®t(SD)¤§½d³ò¬° 73.3¡Ó40.0 mcg/mL~79.9¡Ó41.4 mcg/mL¡A 300 mg ¨C¶gµ¹ÃĤ@¦¸ªºÃ©wª¬ºA³Ì§C¥§¡¿@«×¡Ó¼Ð·Ç®t(SD) ¤§½d³ò¬° 173 ¡Ó 75.9 mcg/mL~193¡Ó77.0 mcg/mL
Dupilumab SCª`®g¤@¦¸ ¥ÍÅé¨Ï¥Î²v约64%¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
Dupilumab ¤T´ÁÁ{§Éµ²ªG¡A¨C¶g¤@针»P¨C¤G¶g¤@°w¡AÀø®Ä¬Û·í¡C
¬G¥Î¤G¶g¤@°w¬°¤W¥«¼Ð·ÇÀøªk¡C
Dupilumab ¤G¶g¤@°w¬°³Ì¨ÎÀøªk¡A¦h¥´¦¸¼Æ¤Î¼Æ¶q¡A·|³Q¨Åé§l¦¬约36%/¨ä¥L´N¦b¦å²G¤¤¡A¼W¥[¦å²G¤¤ÃĪº¿@«×¡C ¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 lb¦b´M§ä³Ì¨ÎÀø®Ä¡A µ¥«Ý¡A5¤ë31¤é¸Ñª¼600mg组¡A24+12¦ìªº¼Æ¾Ú¡I
2b ±N±´°Q2¶g/©Î¥|¶g¤@°w¡H¦óªÌ¬°¨Î¡I 600mg ¥|¶g¤@°w¡A³Ì¥i¯àªº¿ï¾Ü¡A 400mg 则¥i¯à¦¨¬°¡A¨â¶g¤@°wªº³Ì¨Î¡C
¤@¯ë¥Íª«»s¾¯©e¥~»s³y¦¨¥»约²b¾P°â额15%-20%¡A ¦Û¦æ»s³y约10%.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/7 ¤W¤È 09:00:20
²Ä 3926 ½g¦^À³
|
ȱoª`·Nªº¬O¥»¦¸¤½§iªº´Á¤¤¼Æ¾Ú¡A600mgÁÙ¤Ö3¤H¡A18¤H¥iµû¦ô·í¤¤ÁÙ¦³3¦ì¨ü¸Õ¬O¨S¦³¥´§¹§¹¾ãªº¤K°w¡A¹w´Á§¹¾ã¤@´Á¤ÀªR¼Æ¾Ú·|§ó«G²´¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/3/7 ¤W¤È 08:16:59
²Ä 3925 ½g¦^À³
|
pharm.cch.org.tw/index.php/research/2018-10-05-03-06-36/203-101-mirabegron-5 ¹ü°ò¦³°Q½× ¥[½X¨È·à±d |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·RµL10148552 |
µoªí®É¶¡:2021/3/6 ¤W¤È 10:45:30
²Ä 3924 ½g¦^À³
|
¦U¦ì¤j¤j§A̦n¡G ¦Û¤v¬üªÑ½Æ©e°U±Ä¥Îªº¬O´I¨¹ÃÒ¨÷¡A¦³»Ýn¥i¥H¤¶²ÐÀç·~û¡A¤âÄò¶O¤H¤u³æ0.25%ºô¸ô³æ0.15%¡A¡]·í¤Ñ¦PªÑ²¼¦P¤è¦V²Ö¥[ºâ¡^ §C¦¬¦p¤U¡G ¬üªÑ20¬üª÷ ´äªÑ25´ä¹ô ¤éªÑ1500¤é¹ô ·sªÑ21·s¹ô/21¬üª÷/100´ä¹ô ¼wªÑ25¼Ú¤¸ ^ªÑ20^Âé
¨ä¥L¶O¥Î½Ð°Ñ¦Ò©xºô www.fubon-ebroker.com/WorldWideStocks/Introduce |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/6 ¤W¤È 09:50:04
²Ä 3923 ½g¦^À³
|
»Û£¤j¡A§Ú¤]¬O¥Î½Æ©e°U¡A¤âÄò¶O¯uªº«Ü°ª ¦pªG±z¦b·N¤âÄò¶O¡A¥i¥H¥Îfirstrade |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/6 ¤W¤È 08:57:13
²Ä 3922 ½g¦^À³
|
¬Q¤é²×©ó¦¬¤F¬õ¤U¤Þ½u¡Aµu½u§CÂIÀ³¸Ó¤w¸gº¡¨¬¡A¤U©P¶}©l¦³¾÷·|¶}©l½L¾ã¤£n¦³¤j¾_Àú¡AµM«á¶}©l¦V¤W§ð°í |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/6 ¤W¤È 04:19:59
²Ä 3921 ½g¦^À³
|
www.nejm.org/doi/full/10.1056/nejmoa1610020 Dupilumab ¤T´Á2ÓÁ{§ÉªºÀø®Ä¡A¦p¹Ï¤G¡C
¨C¶g¤@针vs¨C¤G¶g¤@针¤§Àø®Ä¡A´X¥GµL®t²§¡C
²Ä12¶g¥i¹FûßÈ¡C
²Ä8¶g®tûßÈ3%-5%¡C
YASLAN004 ¥¼¨Ó 2b ¨C¤G¶g¤@°w¡A¤Î¨C¥|¶g¤@°w¡A©Ôªø16¶gªvÀø¡C
EASIªº¥§¡°´T¡A·|¦³3%-5%Àu©ó¥Ø«e1b¨C¶g¤@°wx8¶gªºÀø®Ä¡C
´Nµ¥¥¼¨Ó2bÁ{§ÉÅçÃÒ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/3/6 ¤W¤È 12:00:03
²Ä 3920 ½g¦^À³
|
¥i¥H¤£n¦A¶^¤F¶Ü... ¥B¨C¦¸¶^´T³£¦n¤j...
«Ó°¶¤j ¬O¥Îþ¤@®a¨÷°Ó? §Ú¥Î½Æ©e°U¤âÄò¶O¦n¶Q... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/5 ¤U¤È 11:26:35
²Ä 3919 ½g¦^À³
|
¶^¦n¤j ¨ºÓ4¤¸²{¼Wªº·|¤£·|«Ü¹Ãªü §Ú¤µ¤Ñ¨Ó¤£¤Î´«¬ü¤¸¡A¤£µM¦n·Q¦A¥[½X |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/5 ¤U¤È 10:56:17
²Ä 3918 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/3/5 ¤U¤È 10:52:26
²Ä 3917 ½g¦^À³
|
«Ó°¶¤j... §Ú¤S½Ä¤F¡A¤µ¤Ñ¤Ó²ÖºÎı¥h ¤£ºÞ¤F... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/5 ¤U¤È 10:25:08
²Ä 3916 ½g¦^À³
|
§Æ±æ¤µ¤Ñ¯à°÷¤î¶^æí3.55 ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/5 ¤U¤È 06:58:36
²Ä 3915 ½g¦^À³
|
³o¤T¦~ªº¤é´Á³£¤£¦P ¦³¦~¤¤ ¦~ÀY n¬Ý¥L̦ó®É³qª¾ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/5 ¤U¤È 06:36:10
²Ä 3914 ½g¦^À³
|
¥h¦~Âà´«¦n¨ì²{¦b³£ÁÙ¨S³Q¦¬ºÞ²z¶O ½Ð±Ð©ú¤Ñ¤j¬O¦ó®É¦¬ªº©O? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/5 ¤U¤È 05:46:57
²Ä 3913 ½g¦^À³
|
³o¤T¦~¨C¦~³£¦¬0.03¤µ¦~¤]¤£¨Ò¥~ 2830 * 0.03 = 84.9 usd |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/3/5 ¤U¤È 05:09:13
²Ä 3912 ½g¦^À³
|
°Q½×°Ï-¥¼¤W¥«°Q½×°Ï-F¨È·à-´«ADR¿ìªk
¬ü°ê¦s°U¾ÌÃÒ¸g¬ö°Ó«OºÞ¶O¡G ¶R¶i¬ü°ê¦s°U¾ÌÃÒ¦p©ó«OºÞ¶O¥Î¦¬¨ú°ò·Ç¤é®É©|¦³«ùªÑ¡A±N·|³Q¬ü°ê«OºÞ¾÷ºc ¦¬¨ú«OºÞ¶O¥Î¡C¬ü°ê¦s°U¾ÌÃÒ«OºÞ¶O¬ù¨CªÑ 0.01 ¬ü¤¸¦Ü 0.05 ¬ü¤¸¤£µ¥¡A¨C¥b ¦~¡B¤@¦~©Î©w´Á¦V«ù¦³¤H¦¬¨ú¤@¦¸¡A¨ãÅé¶O¥Î¨ú¨M©ó±zªºÃÒ¨é¸g¬ö°Ó¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/3/5 ¤U¤È 04:02:38
²Ä 3911 ½g¦^À³
|
§Ú°O±o¨È·à±d¦³»¡©úºÞ²z¶Oªº¦¬ªk..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/5 ¤U¤È 03:26:45
²Ä 3910 ½g¦^À³
|
¾Ú§Ú©Òª¾ ¨CÀÉADR¤£¤@©w³£·|¦¬ºÞ²z¶O ¦pªGn¡An¦¬¦h¤Ö¤]¥u¦³¤½¥q¦Û¤vª¾¹D §Úı±o·à¤l¦³¥i¯à¤£·|¦¬ºÞ²z¶O ¦]¬°¤@¯ë¦pªG¦³¦¬³£¬O¦b¦~©³¦¬ ¥h¦~©³¨é°Ó¨Ã¨Sn¨D§Ún¥æ«OºÞ¶O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/3/5 ¤U¤È 03:04:22
²Ä 3909 ½g¦^À³
|
©êºp,¥´ÂZ¦U¦ì¤j¤j°Q½×. ·Q½Ð±Ð¦U¦ì¤j¤j §Ú¶R¤F¨È·à±dADR 2830ªÑ ¨C¦~ªººÞ²z¶O¬O¦h¤Ö?? ¦³ºâªk¶Ü?? ÁÂÁÂ,¯¬§ë¸ê¶¶§Q.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤U¤È 02:08:40
²Ä 3908 ½g¦^À³
|
¤T¤jÃÄÁ{§É ¹êÅç²Õ°ò½u (¥ÎÃÄ«eEASI&BSA«ü¼Ðª¬ºA)¤§ PK
¤@.ASLAN004 400mg vs Dupilumab -P3-S1 vs Lebrikizumab P2
1.EASI score ¡V mean¡C (1)30.9 //(2) 33.2¡]3)25.5
ASLAN004 400mg vs Dupilumab 30.9/33.2=93% (Dupilumab ¤ñ ASLAN004 400mg ÄY«7%)
ASLAN004 400mg vs Lebrikizumab 30.9/25.5=121%(ASLAN004 400mg ¤ñ Lebrikizumab ÄY«21%) Dupilumab VS Lebrikizumab 33.2/25.5=130%(Dupilumab ¤ñ Lebrikizumab ÄY«30%)
2.BSA ¡V mean (1)59.8%//(2)56%//(3)40%
ASLAN004 400mg vs Dupilumab 59.8%/56%=107%(ASLAN004 ¤ñ Dupilumab 400mg ÄY«7%)
ASLAN004 400mg vs Lebrikizumab 59.8%/40%=150%(ASLAN004 400mg ¤ñ Lebrikizumab ÄY«50%)
Dupilumab VS Lebrikizumab 56%/40%=140%(Dupilumab ¤ñ Lebrikizumab ÄY«40%)
¤G.ASLAN004 600mg vs Dupilumab-P3-S1 vs Lebrikizumab P2
1.EASI score ¡V mean¡C (1)32.5 //(2) 33.2¡]3)25.5 ASLAN004 600mg vs Dupilumab 32.5/33.2=98% (Dupilumab ¤ñ ASLAN004 400mg ÄY«2%)
ASLAN004 600mg vs Lebrikizumab 32.5/25.5=127%(ASLAN004 400mg ¤ñ Lebrikizumab ÄY«27%)
Dupilumab VS Lebrikizumab 33.2/25.5=130%(Dupilumab ¤ñ Lebrikizumab ÄY«30%)
2.BSA ¡V mean (1)56.3%//(2)56%//(3)40%
ASLAN004 600mg vs Dupilumab 56.3%/56%=100%(¨â²Õ¬Û¦P) ASLAN004 600mg vs Lebrikizumab 56.3%/40%=141%(ASLAN004 400mg ¤ñ Lebrikizumab ÄY«41%) Dupilumab VS Lebrikizumab 56%/40%=140% (Dupilumab ¤ñ Lebrikizumab ÄY«40%)
***ESAI: An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). It takes a few minutes and experience to calculate it accurately. Then it¡¦s easy! EASI score does not include a grade for dryness or scaling. EASIµû¤À¬O¤@ºØ¥Î©ó´ú¶q¯SÀ³©ÊÀã¯lªºµ{«×¡]±¿n¡^©MÄY«µ{«×¡]Àã¯l±¿n©MÄY«©Ê«ü¼Æ¡^ªº¤u¨ã¡C »Ýn´X¤ÀÄÁ©MÂ×´Iªº¸gÅç¤~¯à·Ç½Tpºâ¥X¥¦¡C ¨º«Ü²³æ¡I EASI¤À¼Æ¤£¥]¬A°®Àê©Îµ²«¯µ¥¯Å¡C
***BSA: Body Surface Area (¨ÅéÀã¯lªí±¿n)
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/3/2 ¤U¤È 09:26:06²Ä 46 ½g¦^À³ ¤j®aµo¤F
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
¤½¥q²¤¶¤¤
p7 vs. p17
°ò缐ªºPK ¤ñ¸û
ASLAN004 ¤Ï¦Ó§ó±µªñ Dupilumab ¤T´Á¤§°ò缐¼Æ¾Ú °ò½u¼Æ¾Ú𠃊ebrikizumab 2b ¤Ï¦Ó¤ñASLAN004 ¤Îdupilumab ¸û»´¯g
¬Ý§¹§ó¥[½T©wASLAN004 ¯uªº¤ñDupilumab ,¦P¼Ë¨C¶g¤@°wªº¼Ð·ÇÀøªkÀø®Ä±j«Ü¦h,«Ü¦h
(1)AS𠃊AN004 400mg-600mg-placebo//(2) dupilumab 300mg/qw s1-s2-placebo//(3)Lebrikizumab
EASI score ¡V mean¡C (1)30.9~32.5-p33.9 //(2) 33.2-31.9-(p 34.5-33.6)¡]3)25.5-p28.9 Patients with IGA 4 BSA ¡V mean ¡]1¡^17%-67%-p60%//¡]2)48%-47%-(p49%-49%)//(3)29%-p39% BSA ¡V mean (1)59.8%-56.3%-p59.8%//(2)56%-52%-p58%-54%//(3)40%-p47%
Abbreviations EASI: Eczema Area and Severity Index IGA: Investigator Global Assessment BSA: Body Surface Area
¦¸¸Ñª¼ 400mg/600mg ESAI 50/75/90 ¡A¯uªº¥O¤HÅåÆv¡C ¨ú±oÃĵýªº¤T´Á«ü¼ÐESAI75,IGA 0,1 §¹³Ó¹ï·Ó²Õ, ©ñ¤j¨ì¤T´Á¤H¼Æ200:200 ,P< 0.0000001 ¦w¥þ©Ê°ª, Åç°R¤w³Q¤TÃĪºMOA¨ú±o¥¿¦Vµ²ªG.
¤T´Áªº¥Dn«ü¼Ð¡A¶W¶VDupilumab¤T´Á«Ü¦h¡A«Ü¦h¡C 1.ESAI50 ASLAN004 89% ,vs ¹ï·Ó²Õ 40% vs dupilumab. 61% 1.ESAI75 ASLAN004 67% ,vs¹ï·Ó²Õ 0% vs dupilumab 50% 2.ESAI90 ASLAN004 56% ,vs ¹ï·Ó²Õ 0% vs dupilumab 33%, 3.¤é«á16¶gªºªvÀøIGA,0,1¤ñ²v ¦Û·|¾aªñESAI-90
¦¨¥\ÅçÃÒM0A¡A¤S¶W¶VÅQ¥DDupiluma ¼Ð·ÇÀøªkªºÀø®Ä¡C
¯uªº¦p¤½¥q¥»¦¸Á{§É结½× robust and differentiated safety and efficacy profile
¦bÁ{§É¼Æ¾Ú¤½§i¤¤¥Îrobust³oÓ¦rªí¥Ü¼Æ¾Ú«Ü¦³Àu¶Õ¡A«Ü¦³Ävª§¼ç¤O¡A¼Æ¾Ú±j¦Ó¦³¤O¡C
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
ASLAN004 400mg/600mgx¨C¶g¤@°w x8¶g vs Dupilumab ¨C¶g¤@°wx16¶g
(¤@).400mg/600mg QW(¨C¶g¤@°w/8¶g)
EASI-50 83%/100% EASI-75 67%/67% EASI-90 67%/33% IGA0/1 17%/33%(¥Dn«ü¼Ð)¡X¡X67%ªºESAI ,IGA 0.1 =17% , ¼Æ¾Úª½ªº©_©Ç¡AIGA0.1 ¤é«á¥²¤W¤Éªñ67%
(¤T)¹ï·Ó²ÕPlacebox8¶g
EASI-50 40% EASI-75 0% EASI-90 0% IGA0/1 0%(¥Dn«ü¼Ð)
¡X¡X¡X¡X¡X¡X Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð(2016¦~¤½¥¬)
(¤@).300 mg QW(¨C¶g¤@°w/16¶g)¡A°_©l¶q600mg
EASI-50 61%/61% EASI-75 52%/48% EASI-90 36%/30% IGA0/1 38%/31%(¥Dn«ü¼Ð)
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%(¥Dn«ü¼Ð)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/3/5 ¤U¤È 12:12:07
²Ä 3907 ½g¦^À³
|
°ò¥»«ùªÑ´N¦n¡A¨ì5¤ë¸Ñª¼ÁÙ¦¡AºCºC¨Ó¡AÆ[¹î¥ý |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/5 ¤W¤È 11:46:01
²Ä 3906 ½g¦^À³
|
§Ú¥»¨Ó·Q»¡¶R¨ì25000ªÑ´N¦n ²{¦b¬Ý¨ì·à¤l³o»ù¦ì¡A®`§Ú¤S·Q¦A¥[½X ¤ß¦nÄo¡A¤£ª¾¹D¦³¨S¦³¬ÝÃaªºªO¤Í¨ÓÀ°§Ú°·Å¤@¤U |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/5 ¤W¤È 11:27:36
²Ä 3905 ½g¦^À³
|
3¤ë¼Æ¾Ú¥¼¤½¶}¤§«e,µ´¤j³¡¤Àªº¤H©êASLN¤ßºA¬O½äªº¦¨¤À©~¦h,3¤ë¥÷¼Æ¾Ú¤½¶}«á¤w¸g¤£¬O½ä¤F,¬O¤@Óµ´¨Î§ë¸êªº¾÷·| ! ¦³§C»ù§AÀ³¸Ó¬On¶}¤ßÁÙ¦³¾÷·|°l¥[ªÑ¥÷ ? ¦pªG¤§«á±µªñ2¦rÀY§Ú¨ÌµM·|«ùÄò¥[½X ! ´±©w»ù4¶ô¿ú§ë¸ê6000¤d¸U¬üª÷ªº¤H¥i¤£¬O³Í¤l,¤d¸U¤£n³Qªñ¤éªºªÑ»ù¶^´TÀ~¨ì½æ¥X,·í§A½æ¥X¤F,6¤ë¤§«á§AªÖ©w·|©ê¾Ñ²×¥Í! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤W¤È 10:41:38
²Ä 3904 ½g¦^À³
|
¥Ø«e¥«È70,000¤dªÑx3.31=2.3»õ¬ü¤¸
¤½¥q«O¦³1.14»õ现ª÷¡A¦©°£0.2»õ负债¡C
²bȪñ9000¸U¬ü¤¸¡C
«K©y¨ìÃz¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/5 ¤W¤È 10:01:40
²Ä 3903 ½g¦^À³
|
¤Ñ©R¤j
Âå¾Ç±M·~¦b¤½¥q¬ãµo¹Î¶¤»P±M®aÅU°Ý¤¤¡A¥¼¨ÓASLAN2b¤H¼Æ,¾¯¶q,Æ[¹î®É¶¡,Àø®Ä«ü¼Ð·|¦p¦ó³]p ´N©ñ¤ß¥æµ¹¤½¥q¬ãµo¹Î¶¤»P±M®aÅU°Ý |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤W¤È 09:16:04
²Ä 3902 ½g¦^À³
|
¥¼¨Ó5¦~¡A¥i赚30-4O¿ªº谮¤OªÑ¡C
¬OÃø±o¾÷¹J(Y¤£³Q¨ÖÁÊ) 2-3¦~¨ÖÁÊ»ù50¬ü¤¸¥ª¥k¡A¤]¦³15¿¥i赚¡C
¦³缘ªÌ©~¤§¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/3/5 ¤W¤È 08:56:34
²Ä 3901 ½g¦^À³
|
6¤¸¥i¤£¬O§Ú´Á«Ýªº»ù®æ¡A¹çÄ@µ¥¤[¤@ÂI¡A¤]¤£¯à Åý¾÷·|¸¨« Ó¤Hı±o²¢»e»ù®æ¤S¥X²{¡A3.4¤p¥[°¨¤@¨Ç Ãz¥¨¶q«á·Q¥[Áʪº¡A¤À¨â¤T§åÁʤJ ¥i¤À´²·ÀI¡A¶R¤£°÷Åý¥L¸°ª¤@¼Ë¶}¤ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤W¤È 08:54:10
²Ä 3900 ½g¦^À³
|
内³¡¼úÀy 2014/2017¦~¡A约3000¤dªÑADR¡A¥§¡³æ»ù¡A3.6¬ü¤¸¡C(©|¥¼µo¦æ)
2020¦~¡A约5000¤dªÑADR¡A¥¼¨Ó10¦~µo¦æ¡A³æ»ù¥¼©w¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤W¤È 08:43:33
²Ä 3899 ½g¦^À³
|
¥»½ü¶Ò资¬¡°Ê 1.¤½¶}¥«Ô·¾P°â¡A¶Ò±o2400¸U¬ü¤¸¡A¥§¡³æ»ù约3¬ü¤¸x约8000¤dªÑADR¡C
2.¨p¶Ò1800¸U¬ü¤¸¡A³æ»ù3.52¬ü¤¸¡A5110¤dªÑADR¡A©|¥¼¥æ³Î¡C(30¤Ñ¤º¥æ³Î) 3.¥]¾P6000¸U¬ü¤¸¡A³æ»ù4¬ü¤¸¡A¤µ¤Ñ¥æ³Î¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2021/3/5 ¤W¤È 08:35:20
²Ä 3898 ½g¦^À³
|
¦³ÂI¾Ò®¬6¶ô¦hªº®ÉÔ¨S¦³n¥ý§â¥»ª÷¦¬¦^¨Ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤W¤È 07:19:58
²Ä 3897 ½g¦^À³
|
¦¸6000¸U¬ü¤¸¶Ò资¡A¥Dn¥Î¦bASLAN004 2b AD Á{§É¡C ¦ôp250-280¤H¡A16¶g¡C
¥¼¨Ó¤T´Á¡A°£16¶gÁ{§É¥~¡A¥t¥[©µ¦ù©ÊÁ{§É¦Ü52¶g¡A¥i¯à¦³¤ÏÀ³¨C¥|¶g¤@°w¡A
¤T´Á须2Ó400¤HªºÁ{§É¡A¦@800¤H
6000¡Ñ800/280¡Ñ2=3.4»õ¬ü¤¸
¥t¥[¡Aý³Ý/MS¡C¤G´ÁÁ{§É¡A¦Xp5»õ¬ü¤¸¡A¥[3¦~ªºÀç¹B资ª÷¡A7000¸U¬ü¤¸¡A¥t¤ä¥ICSL3000¸U¬ü¤¸ªºùµ{ª÷¡A¦@6»õ¬ü¤¸ªº¸êª÷»Ý¨D¡C
18Ó¤ë¨ú±o¡A¥Dn¼Æ¾Ú¡C
2022¦~¡A¦~¤¤¶}©l¡A (1)«D¬ü区ªº±ÂÅv¤jÀ¸±N¶}©l¡A³Ì°ª18»õ¬ü¤¸ªº¾P°â额¡A 18»õ¬ü¤¸¡Ñ22%ñ约ª÷+¾P°â¤À¼í¡Aµu´Á资ª÷¥i¨ú±o约3»õ¬ü¤¸¡A (2)µM«á¤½¥¬2b¸Ñª¼³ø§i¡A¦P®É¥]销¨î¡Aªº¤½¶}¥«Ô·¶Ò资3»õ¬ü¤¸¡C
Y¼W资15,000¤dªÑADR(2022¦~Q3/Q4)
»ù®æ须©Ô¤W20¬ü¤¸/ADR¡A¤è¯à¶Ò±o3»õ¬ü¤¸¡C
85,000¤dªÑ(ªÑ¥»)¡Ñ20=17»õ¬ü¤¸ªº¥«È¡A ¦Ó¤½¥q³Q¨ÖÁÊ»ùÈ约¦b42»õ¬ü¤¸¡C
17/42=40%
¨ÖÁÊ»ù¥«È½¤@¿¥H¤W±`¨£¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤W¤È 06:42:41
²Ä 3896 ½g¦^À³
|
¥»¦¸6000¸U¬ü¤¸ªº¶Ò¸ê±Ä¥]¾P¨î¡A»P¤T¤j©Ó¾P¨é°Ó¦X约¤x¸g¤W¶Ç¡C ir.aslanpharma.com/financial-information/sec-filings 3¤ë4¤é¡A¤W¶Ç¬ü°êµý´Á·|¡A²Ä¤GÓÀÉ®× P.45 ñ¸p¤H¬°¤½¥q¨CªÑ±È0.01¬ü¤¸ªº´¶³qªÑ¡]¡§ªÑ¥÷¡¨¡^©Î¥iÂà´«¬°¥i¥æ´«ÃҨ骺©Ò¦³ªÌ¡C ©Î¥i¦æ¨ÏªÑ¥÷¡C¥»¤½¥q«Øij¶i¦æ¤½¶}µo°âªÑ¥÷¡A¨ä§Î¦¡¥i¥H¬O¬ü°ê¦s°U¾ÌÃÒ¡C ¥»¤½¥q¡]¥H¤U²ºÙ¡§ ADS¡¨¡^¡A¤À§O¥Nªí¤ªÑªÑ¥÷¡]¡§n¬ù¡¨¡^¡AJefferies LLC¡]¡§ Jefferies¡¨¡^©MPiper Sandler¡]¡§ Piper¡¨¡^±N¤À§O¥R·í¥»¤½¥qªºªÑ¥÷ ©Ó¾P°Óªº¥Nªí¡Cñ¦W¤H½T»{¡A¥»¦¸µo¦æ±N¨Ï¥»¤½¥q©Mñ¦W¤H¦U¦Û¨ü¯q¡C³o ñ¸p¤H©Ó»{©Ó¾P°Ó¨Ì¿à¥»«H¨ç¨óij¤¤©Ò¥]§tªºÃ±¸p¤Hªº³¯z©M¨óij ¶i¦æµo°â¡A¨Ã©óÀH«á¤é´Áq¥ß¥]¾P¨óij¡]¡§¥]¾P¨óij¡¨¡^¤Î¨ä¥L »P¥»¤½¥q¦³Ãöµo°âªº©Ó¾P¦w±Æ¡C ªþ¥óA¦C¥X¤F¥»«H¨ç¨óij¤¤¥¼¨Ï¥Îªº¤j¼g³N»yªº©w¸q¡C¨º¨Ç ©w¸q¬O¥»¨óij®Ñªº¤@³¡¤À¡C ¦Ò¼{¨ì«ez¤º®e¡A¨Ã¥X©ó¨ä¥L¨}¦n©MÄ_¶Qªº¦Ò¼{¡A¯S¦¹½T»{¨ä¦¬±x©M¥R¤À©Ê¡A ñ¸p¤H¯S¦¹¦P·N¡A¦b¸T°â´Á¤º¡Añ¸p¤H±N¤£·|¡]¨Ã±NºÉ³Ì¤j§V¤O¨Ï¥ô¦ó®a®x¦¨û ¥¼¸gJefferies©MPiper¨Æ¥ý®Ñ±¦P·N¡A¦b¤£¹H¤Ï¥»«H¨ç¨óij¤¤³W©wªº¨Ò¥~ªº±¡ªp¤U¡A¥i¥H©Úµ´¥L̪º¦P·N¡C ¦Û¦æ¨M©w¦P·N¡G •¥X°â©În¬ù¥X°â¥ô¦ó²{¦s©Î¥H«á¾Ö¦³©Î¹ê¯q¾Ö¦³ªº¬ü°ê¦s°U¾ÌÃÒ¡AªÑ¥÷©Î¬ÛÃöÃÒ¨é¡]©w¸q¨£ ñ¸p¤H©Î¸Ó®a®x¦¨û®Ú¾Ú¡m¥æ©öªk¡n²Ä13d-3±øªº³W©w¡A •¶i¦æ¥ô¦ó±¼´Á¥æ©ö¡A •¹ï®Ú¾Ú¡mÃÒ¨éªk¡n¶i¦æªºµù¥U´£¥X¥ô¦ón¨D©Î¦æ¨Ï¥ô¦óÅv§Q¡A¥Hµo°â©Î¥X°â¥ô¦ó¬ü°ê¦s°U¾ÌÃÒ¡A ªÑ¥÷©Î¬ÛÃöÃÒ¨é¡A©Î«P¨Ï¨ä´£¥æµù¥UÁn©ú¡A©ÛªÑ»¡©ú®Ñ©Î©ÛªÑ»¡©ú®Ñ¸É¥R¤å¥ó¡]©Î×¥¿®×©Î Ãö©ó¦¹Ãþµù¥Uªº¸É¥R¡^¡A©Î •¤½¶}«Å¥¬¦³·N¶i¦æ¤Wz¥ô¦ó¤@¶µªº·N¹Ï¡C The undersigned is an owner of ordinary shares, par value $0.01 per share, of the Company (¡§Shares¡¨) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares, which may be in the form of American Depositary Shares of the Company (¡§ADSs¡¨), each representing five Shares (the ¡§Offering¡¨), for which Jefferies LLC (¡§Jefferies¡¨) and Piper Sandler (¡§Piper¡¨) will act as the representatives of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the ¡§Underwriting Agreement¡¨) and other underwriting arrangements with the Company with respect to the Offering. Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this letter agreement. Those definitions are a part of this letter agreement. In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the Lock-up Period, the undersigned will not (and will use reasonable best efforts to cause any Family Member not to), subject to the exceptions set forth in this letter agreement, without the prior written consent of Jefferies and Piper, which may withhold their consent in their sole discretion: • Sell or Offer to Sell any ADSs, Shares or Related Securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned or such Family Member, • enter into any Swap, • make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any ADSs, Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or • publicly announce any intention to do any of the foregoing. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/5 ¤W¤È 06:24:44
²Ä 3895 ½g¦^À³
|
¥xÁÞ¤j¡A
¨Ì±zÂå¾Ç±M·~¡AASLAN 2bÁ{§É³]p¡A·|¦p¦ó¡H ¥H5组¡AÓ¤H¼ÒÀÀ¡A 1.600mg/¨C¥|¶g¤@°w¡Ñ16¶g¡A¦@2400mg 2.400mg/¨C¤G¶g¤@针x16¶g¡A¦@3200mg 3.200mg/¨C¤G¶g¤@针x16¶g¡A°_©l¶q600mg,¦@2000mg 4.400mg/¨C¥|¶g¤@°wx16¶g¡A°_©l¶q600mg,¦@1800mg 5.¹ï·Ó组
¦Xp250-280¤H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/4 ¤U¤È 10:24:01
²Ä 3894 ½g¦^À³
|
ÁÂÁ¤ѩR¤j»¡©ú ¤G´Á¡A¤T´ÁÆ[¹î´Á´N¥i¨ì16¶g¡A¥H´£°ªÀø®Ä«ü¼Ð¤ñ²v¡AÀHµÛ¤H¼ÆÂX¤j«áPÈ«Ü®e©ö¹F¼Ð¡A¦UºØÀø®Ä«ü¼Ð¡A¦w¥þ©Ê@¨ü©Ê¡A¬I¥´¤è«K©Ê¡AÃĪ«Àx¦s©Êµ¥¦³¥þ±§¹³Óªº¼ç¤O¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤U¤È 09:31:30
²Ä 3893 ½g¦^À³
|
¦X¤@¤½¥¬12¦ì¦b¥xÆWªºÁ{§É¼Æ¾Ú¡A¬O¦³¥[TCS ªº¥~¥ÎÃþ©T¾J¨Å»I , ESAI -75% °´T67%¡A¡]¥¼¤½¥¬°ò缐¼Æ¾Ú)
TCS(¥~¥ÎÃþ©T¾J¨Å»I)¦bDupilumab ¤T´ÁADÁ{§ÉªºÀø®Ä±´°Q
Dupilumab FDA ¼ÐÅÒÀÉ
www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf p.15 3Ó¤T´ÁÁ{§Éx16¶gx2¶g¤@°w Trial1 N=224 :224 Trial2 N=233:236 Trial3 N=106:315
Àø®Ä«ü¼Ð ¡X¡X¡X¡X¡X- 1.ESAI-75%¡C
dupilumab trial1/trial2 51%/44% vs ¹ï·Ó²Õ 15%/12% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 69% vs ¹ï·Ó²Õ 23%
2.ESAI-90%
dupilumab trial1/trial2 36%/30% vs ¹ï·Ó²Õ 8%/7% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 40% vs ¹ï·Ó²Õ 11%
3.IGA 0/1 dupilumab trial1/trial2 38%/36% vs ¹ï·Ó²Õ 10%/9% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 39% vs ¹ï·Ó²Õ 12%
¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦X¤@ªºFB825 ¡ÏTCS , 12¦ì IV ,¤G°w/12¶g
ESAI-75%. 67% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤U¤È 09:20:27
²Ä 3892 ½g¦^À³
|
Kim¤j, www1.ndmctsgh.edu.tw/pharm/pic/medinsert/005XOL01.pdf FB825 ¬O Xolair ªº²Ä¤G¥N. ¦P¬O±i¤l¤å敎±Â©Ò±ÂÅv
²Ä¤@¥N¦bAD Á{§É ¨S¦¨¥\.
FB825 ñ¬ùª÷¶È5.3»õ¬ü¤¸(2017°ê»Ú¦æ±¡¶ÈAD ´N¦³15»õ¬ü¤¸Ã±¬ùª÷ªº¦æ±¡¡^¡AÁô§t¥¼¨Ó³Ì°ª¾P°â10.6»õ¬ü¤¸¡]2020¦~4¤ë15¤ê ¦X¤@»PLE0ªº¦@ÃѦX¬ù¡C
¨È·à 2019¦~5¤ë 31¤é , ¦VCSL ASLAN004 ªº ¶RÂ_¡A隠§tªºÃ±¬ùª÷7.8x2=15.6»õ¬ü¤¸¡A
¥Ø«eASLAN004 ±ÂÅv¦æ±¡ ñ¬ùª÷¦b30»õ¬ü¤¸¡C
¡X¡X¡X¡X
¥¼¨Ó FB825 2b ±N§ï¬°SCª`®g¡A¥i¯à¨C¥|¶g¤@°w/©Î¤G¶g¤@°w¡A¨ÌÅ髤ÎIGE¦³¤£¦P¾¯¶q¡A¨C¦¸¥´°w¬O§_¬Ò¶·©â¦å§P©wIgE¡H¤£ª¾. ¥H¤W¬O²Ä¤@¥N Xolair ªº¥é³æ©Ò§e¡C½Ð°Ñ·Ó¤Wzºô¶
²Ä¤G¥NFB825 2b ©|¤£¥u¦p¦ó³]p¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkim10134548 |
µoªí®É¶¡:2021/3/4 ¤U¤È 09:02:29
²Ä 3891 ½g¦^À³
|
¤Ñ©R¤j ¦n¡A «D±`·PÁ±z¤@ª½¥H¨Óªº±M·~¤À¨É¡A¥H¤Î´£¨Ñ¦UºØ¸Ô²Óªº¸ê°T¡A Åý§Ú̦b¨È·à±dªº§ë¸ê¤W¡A¦³§ó¦nªº°Ñ¦Ò©M¨Ì¾Ú¡C ©ó¦¹¡A¥i§_½Ð±Ð±z¡A12¶g¤@°wªºFB825¡A12¤ëªºªk»¡·| ¤]´£¨ìÀø®ÄEASI-75¹F¨ì67¢HÀu©óDupilumab¡A·|¤£·|¬O ASLAN004¥¼¨Ó³Ì¤jªºÄvª§ªÌ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤U¤È 09:00:33
²Ä 3890 ½g¦^À³
|
¥xÁÞ¤j,
5¤ë31¤é±N¤½¥¬ªº¼Æ¾Ú¡A¥uÆ[¹î8¶g¡C
«Ó°¶¤j,
4¬ü¤¸ ¤£·|ÅÜ¡A¤T¤j©Ó销°Ó¦¤w§ä¤j¤á¡A©Î¥ý¦Û¤v¦Y¤U¡A3¤ë5¤ê§¹¦¨ADRsªº¥æ¥I¡C§¹¦¨¦¹®×¡C¤T¤j¨é°Ó¦³15%ªº¿ï¾ÜÅv¥i¼W¥[ÁʶR. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/4 ¤U¤È 08:54:45
²Ä 3889 ½g¦^À³
|
½Ð°Ý¥]¾P¨î¬O¤£¬O«ü¥|¤¸²{¼W¤@©w¦¨¥\? ¤£·|¦]¬°ªÑ»ù¤U¶^¡A¦Ó¤@ª½½Õ°²{¼W»ù |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/4 ¤U¤È 08:53:17
²Ä 3888 ½g¦^À³
|
¤Ñ©R¤j ¨ì¤¤ë©³À³¸Ó¦Ò¼{¥Î16¶g¥h¼ÒÀÀ ¦U¶µÀø®Ä«ü¼Ð½Õ¾ã«á¦A¶i¦æ¼ÒÀÀ pÈ¥²¸û±µªñ¨Æ¹ê¡A¥i参¦Ò¨ºÁûL¶}ÀYªºÃıq²Ä¤K¶g¨ì²Ä¤Q¤»¶g¼W¥[¦h¤Ö¤ñ²v¡A¦A½Õ¾ã¥[¦^ASLAN004 ¡A·|¤ñì¨Ó¤K¶g°ª¤£¤Ö¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤U¤È 08:47:51
²Ä 3887 ½g¦^À³
|
ir.aslanpharma.com/static-files/8374d41f-79f3-4917-b3e4-b146fb668304
¤µ¤Ñ¥¿¦¡¥Ó³ø¶Ò¸êp¹º¡C
¥Ñ¤T®a¨é°Ó©Ó¾P¡A¬Ý¦ü¥]¾P¨î¡H
Underwriter Jefferies LLC 7,350,000 Piper Sandler & Co. 5,850,000
H.C. Wainwright & Co., LLC 1,800,000
Total 15,000,000¡XNUMBER OF ADSs
q»ù 4¬ü¤¸.
p.23 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤U¤È 06:19:38
²Ä 3886 ½g¦^À³
|
¼ÒÀÀ5¤ë31¤é¸Ñª¼600mg , N=24:12 ¤§6¶µÀø®Ä«ü¼Ð PÈ ---(¨Ì´Á¤¤³ø§i¼Æ¦r¼ÒÀÀ)
ASLAN004 VS ¹ï·Ó²Õ
P<5% (¦³²Îp¤Wªº©úÅã®t²§)
(1)¥§¡EASI°´T76% VS 42% P=4.42%
(2)EASI-50 100% VS 40% P=0.014%
(3)EASI-75 67% VS 0% P=0.055%
(4)EASI-90 33% VS 0% P=6.778%-----(©ñ¤j¨ì2b N:50:50,P=0.003%))(2b ¬°16¶gªvÀø ASLAN004 ·|¤É¨ì¬ù45%´Á±æÈ
(5)IGA0/1 33% VS 0% P=6.778%-----(©ñ¤j¨ì2b N:50:50,P=0.003%)(2b ¬°16¶gªvÀø ASLAN004 ·|¤É¨ì¬ù45%´Á±æÈ
(6)Mean reduction in peak P-NRS 39% VS 16% P=30.708%(©ñ¤j¨ì2b N:50:50,P=1.001%))(2b ¬°16¶gªvÀø ASLAN004 ·|¤É¨ì¬ù50%´Á±æÈ)
------------------------------------------------ ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb ASLAN004 600mgx¨C¶g¤@°w x8¶g vs Dupilumab ¨C¶g¤@°wx16¶g
(¤@).ASLAN004 600mg(¨C¶g¤@°w/8¶g) ¥§¡EASI°´T76% EASI-50 100% EASI-75 67% EASI-90 33% IGA0/1 33% Mean reduction in peak P-NRS 39%
(¤T)¹ï·Ó²ÕPlacebox8¶g
¥§¡EASI°´T42%
EASI-50 40% EASI-75 0% EASI-90 0% IGA0/1 0%(¥Dn«ü¼Ð) Mean reduction in peak P-NRS 16% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤U¤È 03:51:32
²Ä 3885 ½g¦^À³
|
¤@¡BIMMU ªÑ»ù¤@¤Ñ¤jº¦100%, ¥«È¤@¤Ñ¤jº¦ªñ100»õ¬ü¤¸. ¥«È193»õ¬ü¤¸
www.barchart.com/stocks/quotes/IMMU/interactive-chart
2016/02/06¦~Àò BTD (·í®ÉªÑ»ù¶È2.5 ¬ü¤¸¤£¨ì) ,¥H¤G´ÁÁ{§É¸ê®Æ¥Ó½ÐÃĵý
----------------------------------------------
²£«~: SACITUZUMAB COVITECAN 2020/04/22 FDA ®ÖãÃĵý
ADC 4´Á¤T³±©Ê¨ÅÀù ¤T½u¥ÎÃÄ
2024¦~¹w¦ô¾P°â15.9»õ¬ü¤¸.
----2024¦~¤Q¤j³Ì¦³»ùȪº·sÃÄ
www.genetinfo.com/investment/featured/item/27596.html?start=1
--------------------- ¦N§Q¼w¬ì¾Ç¥H$ 21B(210»õ¬ü¤¸)ªº»ù®æ¦¬ÁÊImmunomedics
finance.yahoo.com/quote/IMMU/?p=IMMU
¶®ªê°]¸gµøÀW2020¦~9¤ë14¤é
¦N§Q¼w¬ì¾Ç¤½¥q±N¥H210»õ¬ü¤¸ªº»ù®æ¦¬ÁÊImmunomedics¡A¸Ó¥æ©ö¦³±æ¦b2020¦~²Ä¥|©u«×§¹¦¨¡CImmunomedics°õ¦æ¥D®uBehzad Aghazadeh³Õ¤h»PAlexis Christoforous©MBrian Sozzi¤@°_¥[¤JYahoo Financeªº¡m²Ä¤@µ§¥æ©ö¡n¡C
Gilead Sciences to acquire Immunomedics in $21B deal Yahoo Finance VideoSeptember 14, 2020
Gilead Sciences is set to acquire Immunomedics in a $21 billion dollar deal, which is expected to close in the fourth quarter of 2020. Dr. Behzad Aghazadeh, Immunomedics Executive Chairman, joins Yahoo Finance¡¦s The First Trade with Alexis Christoforous and Brian Sozzi to discuss.
¤G¡B-¤é¥»²Ä¤@¤T¦@ 2 ÓADC ±ÂÅvª÷¹F129»õ¬ü¤¸, µ¹^°êAZ, ªÑ»ù¤jº¦500¦h»õ¬ü¤¸,ªñ¤T¦~.----
histock.tw/stock/tv/tvchart.aspx?no=J4568
DS-8201 69»õ¬ü¤¸ ±ÂÅvª÷(¤wÀòMBC 3½u¥H«áªºADC FDAÃĵý) DS-1062 60»õ¬ü¤¸ ±ÂÅvª÷ ¦Xp 129 »õ¬ü¤¸ ³Q±ÂÅvªÌ :ªü´µ§Q±d
med.sina.com/article_detail_100_1_86457.html
7¤ë27¤é¡Aªü´µ§Q±d»P²Ä¤@¤T¦@«Å§G¦b§ÜÅé°¸ÁpÃĪ«¡]ADC¡^»â°ì¹F¦¨«½S¦X§@¡C³o¤@¦X§@¨óij¤Îª÷ÃB°ª¹F60»õ¬ü¤¸¡A¥i¿×ADCÃĪ«»â°ìªº¤@¦¸¤j¤âµ§¥æ©ö¡C
®Ú¾Ú¨óij¡Aªü´µ§Q±d»P²Ä¤@¤T¦@±N¦b¥þ²y°£¤é¥»¥~¦@¦P¶}µo©M°Ó·~¤Æ¹v¦VTrop-2ªº§ÜÅé°¸ÁpÃĪ«DS-1062¡A²Ä¤@¤T¦@±N«O¯d¦b¤é¥»¿W®a¶}µoªºÅv§Q¡C»P¦¹¦P®É¡Aªü´µ§Q±d±N¦V²Ä¤@¤T¦@¤ä¥I10»õ¬ü¤¸¤À´Á¥I´Ú¡]¨óij§¹¦¨®É3.5»õ¬ü¤¸¡A¨óij¥Í®Ä¤§¤é°_12Ó¤ë«á3.25»õ¬ü¤¸¡A¨óij¥Í®Ä¤§¤é°_24Ó¤ë«á3.25»õ¬ü¤¸¡^¡BÃĪ«¤W¥««áÃB¥~¤ä¥I10»õ¬ü¤¸´Ú¶µ¡A¥H¤Î°ª¹F40»õ¬ü¤¸ªº¾P°â¬ÛÃö¨½µ{¸O´Ú¶µ¡C
¾Ú±x¡ADS-1062¬O¤@´Ú¼ç¦bªº«½S·sÃÄ¡A¥Ø«e¥¿¦b¶}¾v¥Î©óªvÀøªí¹FTrop-2ªº¦hºØ¸~½F¡C¦Óªü´µ§Q±d¤]¥i¿×¹ïDS-1062±H¤©¤F«p±æ¡A»{¬°¸ÓÀøªk±N¡§«·s©w¸qªÍÀù¡B¨Å¸¢Àù©M¨ä¥L¦hºØÀù¯gªºªvÀø¼Ð·Ç¡¨¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤W¤È 09:57:26
²Ä 3884 ½g¦^À³
|
Type II Recepter ª¢¯gªºMoA ¤w¸g3ÃÄÅçÃÒ¡A
IL4/IL13ªº°T®§ªý断¡C ¨úADÃĵý100%
§@¥Î¦ì¸m¤£¦P¡AÀø®Ä¤£¦P¡A°Æ§@¥Î¤£¦P¡C
ASLAN004 > Dupilumab>Leberizumab¡ADup 75%>Talkibizumab¡ADupªº50% |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 2701 ~ 2800 «h¦^ÂÐ >> |